European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): general report of activities 1999. by unknown
General report
of activities
1999
This report is also available in French and German.
All translations were made by the Translation Centre for the Bodies of the European Union.
Information on the EMCDDA can be found on its website (http://www.emcdda.org).
A great deal of additional information on the European Union is available on the Internet.
It can be accessed through the Europa server (http://europa.eu.int).
Cataloguing data can be found at the end of this publication.
Luxembourg: Office for Official Publications of the European Communities, 2000
ISBN 92-9168-091-5
© European Monitoring Centre for Drugs and Drug Addiction, 2000
Reproduction is authorised provided the source is acknowledged.
Printed in Belgium
3Foreword 5
Franz J. Bindert
Chairman of the EMCDDA Management Board
Introduction 7
Georges Estievenart
Executive Director of the EMCDDA
EMCDDA 1998–2000 work programme 12
Chapter 1 13
Epidemiology
Chapter 2 29
Demand reduction
Chapter 3 39
Reitox coordination
Chapter 4 47
National and Community strategies
Chapter 5 55
Information strategies and communication resources
Chapter 6 69
Administration, finance and logistics
Chapter 7 75
The EMCDDA and its statutory bodies
Chapter 8 79
The EMCDDA and its partners
Contents

(1) Members of the EMCDDA Management Board and Scientific Committee and representatives 
of the national focal points (NFPs) of the Reitox network are listed on the Centre’s website 
(http://www.emcdda.org).
5
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has
great pleasure in presenting its fifth General report of activities to the European
Parliament, the Council of the European Union, the European Commission and the
Member States, following its adoption by the Centre’s Management Board on 14
January 2000.
The report provides a retrospective account of the EMCDDA’s activities and accom-
plishments in 1999 at the mid-point of its second three-year work programme
(1998–2000) and five years after its establishment in Lisbon.
My particular congratulations go to Georges Estievenart, Executive Director of the
EMCDDA, whose re-election for a second five-year term by the Centre’s
Management Board in July 1999 is a tribute to his commitment and his work. On
behalf of the Management Board, I would like to thank him, his colleagues at the
EMCDDA as well as the national focal point staff and members of the Scientific
Committee for their contribution to the year’s successes (1).
1999 was a special year for the Centre in which reflection and evaluation took the
front seat. In July, the director presented to the Management Board his proposed
medium-term perspectives for the agency for the period 2000–04, which, together
with the new European Union drugs strategy covering the same period, are the 
subject of ongoing discussions in the context of the EMCDDA’s 2001–03 work 
programme. Also in 1999, at the request of the Management Board and the
European Commission, the Centre became the first decentralised EU agency to
undergo an external evaluation of its activities by private consultants. The results of
this exercise, gathered at the end of the year and due in spring 2000, will help the
Centre, its statutory bodies and the Reitox network take stock of progress and chart
the optimal path in the new millennium.
Franz J. Bindert
Chairman of the EMCDDA Management Board
January 2000
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(2) The annex to the EMCDDA’s founding Regulation (EEC) No 302/93 of 8.2.1993 lists five priority areas.
See the following website (http://www.emcdda.org/about/ec_regulation.shtml).
(3) Joint Action 97/396/JHA of 16 June 1997 adopted by the Council on the basis of Article K.3 of the Treaty
on European Union, concerning the information exchange, risk assessment and the control of new
synthetic drugs (Official Journal L 167, 25.6.1997). 
(4) Council decision of 13 September 1999 defining 4-MTA as a new synthetic drug which is to be made
subject to control measures and criminal penalties (Official Journal L 244, 16.9.1999).
In 1999, as it reached the mid-point of its second three-year work programme
(1998–2000), the EMCDDA consolidated existing, or embarked on new, activities
under the programme’s six priority objectives. These six objectives relate to the first
two priority areas of activity defined by the Centre’s founding regulation: the
demand for drugs and the reduction of that demand; and national and Community
strategies and policies (2).
This brief introduction will not attempt to enumerate all the Centre’s achievements
in 1999, but will let the different chapters speak for themselves. It will, however,
highlight what were among the most significant developments and occasions for
the EMCDDA during the year and will describe, where relevant, the context in
which these occurred.
One of the Centre’s major successes of 1999 related to the joint action on new syn-
thetic drugs, adopted in June 1997 by the Council of the European Union (3). In
January 1999, the EMCDDA and Europol presented preliminary data to the Council
on a new synthetic drug, 4-MTA (4-methylthioamphetamine), which had triggered
concerns late in 1998 following a number of deaths allegedly linked to the sub-
stance. Their initial findings led the German Presidency of the EU to refer the drug
back to the two agencies in February for a formal risk-assessment procedure under
the terms of the joint action. Four months later, a full assessment of the drug con-
cluded that 4-MTA should be controlled in the EU, largely due to the high risk of
overdose associated with it. By September, the EU Council of Justice and Home
Affairs had adopted a decision to this effect, defining 4-MTA as a drug to be sub-
mitted to ‘control measures and criminal penalties’ in the 15 Member States (4).
From start to finish the process had taken approximately six months, confirming the
speed and effectiveness of the early-warning and risk-assessment mechanisms pro-
vided by the joint action. The experience also illustrated how the EMCDDA can
successfully combine its data-collection and scientific-evaluation expertise to influ-
ence decision-making on drugs in Europe.
As always, a highpoint of the year was the launch of the EMCDDA’s Annual report
on the state of the drugs problem in the European Union which, in 1999, was held
in Berlin. The report was presented to the German and European media on 
22 November in cooperation with the German drugs coordinator, Christa Nickels,
and the German Ministry of Health, in the presence of the chairman of the 
EMCDDA Management Board and members of the Centre’s staff. The Spokesman’s
Service of the European Commission also announced the report simultaneously in
Brussels, while other promotional activities were carried out by the Reitox national
focal points (5). As a result of these events, the report obtained record coverage in
the media, which, in turn, boosted the Centre’s visibility among its primary audi-
ences, European and national decision-makers being at the fore.
Evaluation of drug prevention continued to be a pertinent issue for the agency in
1999 with work culminating in December in the second European Conference on
the Evaluation of Drug Prevention, ‘Evaluation: a key tool for improving drug pre-
vention’, held in Strasbourg. The conference, jointly organised by the EMCDDA and
the European Commission, aimed to promote a shift in ideology towards greater
evaluation of drug-prevention initiatives. The Centre firmly believes that only when
drug programmes are routinely evaluated can we be sure that money used to tackle
the drugs problem is well spent. The conference adopted a set of recommendations
to facilitate and promote an ‘evaluation culture’ in drug-prevention programmes and
strategies in the EU Member States.
This leads me to one of the most significant political developments of the year for
the EMCDDA: the drafting of the European Union drugs strategy 2000–04 (6). The
Centre played an active role in the development of this strategy, notably in promot-
ing the concept of evaluation and the importance of reliable and comparable infor-
mation on drugs as a basis for sound political decision-making. It also hosted an
informal drugs forum on the strategy in July in cooperation with the former
European Commissioner responsible for justice and home affairs, Anita Gradin. I am
pleased to report that the final strategy puts forward a number of new and signifi-
cant elements in the areas of evaluation, information, research and coordination on
drugs that are of immediate interest to the EMCDDA and directly linked to its work.
The European Parliament adopted a formal opinion on the strategy in November,
following a report by its Committee on Citizens’ Freedoms and Rights, Justice and
Home Affairs (formerly the Committee on Civil Liberties and Internal Affairs). The
December European Council meeting in Helsinki then invited the European institu-
tions and bodies concerned by the strategy to proceed rapidly with its implementa-
tion and to report on initial results by the end of 2002. The Centre looks forward to
playing an active role over this period.
On the issue of reliable information on drugs, I would like to say a few words about
the Centre’s work in the area of epidemiology, where great strides are being made
in developing instruments and standards relating to five key indicators of drug use
and related problems in the EU. These indicators, which will be progressively
implemented over the next five years, are designed to increase the quality and com-
parability of the data collected by the Centre and are currently one of the agency’s
prime initiatives.
In addition to improving data quality and comparability, increasing the policy-
relevance of data collected is also essential. To this end, epidemiological work is
underway to develop scientific analyses of how and why different drug-use patterns
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(5) Reitox, the European information network on drugs and drug addiction, consists of one national focal
point from each European Union Member State, one from the European Commission and one observer
focal point from Norway (see Chapter 3).
(6) The strategy follows on from the draft EU action plan to combat drugs (2000–04) first tabled by the
European Commission in a communication to the Council of the EU and the Parliament on 26 May 1999
under the German Presidency of the EU. The plan succeeded the ‘Post-1999 drugs strategy’ (Doc.
7930/2/98 Rev 2. Cordrogue 26 of 2.6.1998) endorsed at the European Council in Cardiff in June 1998 and
the conclusions of the Vienna European Council in December 1998, which requested the Council, the
European Commission and the Parliament to further develop this strategy into a comprehensive plan
in the light of new possibilities offered by the Amsterdam Treaty.
and problems arise and what factors influence their evolution. This, in turn, will
help achieve an understanding of the drug phenomenon that will help better define
and assess different policy options. Examples include quantitative and qualitative
analysis both of emerging and changing trends and of some of the social and eco-
nomic aspects linked to drug availability, use, addiction and their consequences.
The Reitox network, as ever, was the Centre’s backbone in 1999, playing a crucial
role in its programmes via the execution of a number of ‘core tasks’. These tasks
included: promoting the five key epidemiological indicators at national level; pro-
viding essential input to the EMCDDA’s Annual report; promoting mechanisms at
national level under the joint action on new synthetic drugs; and actively publicis-
ing the Centre’s demand-reduction database, EDDRA (Exchange on drug demand-
reduction action). The national focal points also implemented the paper on ‘The
role and financing of the national focal points’, adopted the previous year by the
Centre’s Management Board, and held their first internal Reitox meetings, chaired
by the recently elected Reitox spokesperson (Portuguese Focal Point). EMCDDA-
Reitox topic-focused meetings were also organised in 1999 to ensure adequate 
coverage of important issues.
In the area of information, the Centre further developed its on-line products in 1999,
producing its first CD-ROM (European Union legal texts on drugs) (7) and launching
a new-look website (http://www.emcdda.org), following a project to restructure and
redesign the site to improve navigability and ease of access. An EMCDDA Intranet
was also created during the year to enhance communication and information
exchange inside the Centre. Meanwhile, in the area of documentation, the EMCDDA
hosted the 11th annual meeting of the European Association of Libraries and
Information Services on Alcohol and other Drugs (ELISAD) in November which took
as its theme ‘Organising professional information on alcohol and drug abuse in
Europe’. Furthermore, the Centre stepped up its media activities by preparing the
ground for a formal media strategy and developing new contacts with the written
and broadcast media across Europe.
Beyond the four walls of the EMCDDA headquarters, cooperation continued with
the Centre’s six priority international partners in 1999. It was a great pleasure for me
to sign a memorandum of understanding (MOU) in September with the Council of
Europe (Pompidou Group) alongside the new Secretary-General of the organisation,
Walter Schwimmer. This was the second MOU established by the Centre with a
partner organisation, the first concluded in 1998 with the United Nations
International Drug Control Programme (UNDCP). Meetings were held in the second
half of the year with Pino Arlacchi, Executive Director of the UNDCP, and with
Christopher Luckett, Head of the Pompidou Group secretariat, to discuss imple-
mentation of these agreements. A similar MOU with the World Health Organisation
(WHO) was also discussed by the Centre’s Management Board and is scheduled for
signature in 2000.
In 1999, the Centre’s external relations once again involved cooperation and con-
tacts with regions outside the European Union, notably with central and eastern
Europe; the United States; and Latin America.
In the context of the forthcoming accession to the EU by a number of the central
and east European countries (CEECs), the EMCDDA continued its cooperation with
the Phare multi-beneficiary drugs programme as one of the priority objectives of its
9
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(7) A full list of EMCDDA publications and on-line products released in 1999 is given in Chapter 5. Full
details and ordering information are available at the following address (http://www.emcdda.org/
publications/publications.shtml).
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three-year work programme. In February 1999, the Phare project on drug informa-
tion systems (DIS), which assisted the CEECs in developing an information network
similar to Reitox (by setting up prototype national focal points in each participating
country), completed its final phase. Following a decision by the European
Commission and EMCDDA Management Board during the year, an eventual trans-
fer of the DIS activities to the Centre was explored in 1999 that would allow closer
ties between the EMCDDA and specialised drug information centres in the CEECs.
Cooperation with the United States was marked by the visit to the Centre in October
of Barry R. McCaffrey, Director of the United States White House Office of National
Drug Control Policy (ONDCP). The purpose of the visit was to exchange views with
the Management Board and staff of the EMCDDA and to discuss cooperation and
exchange of information on drugs in general. The visit was Director McCaffrey’s
second to the Centre following his trip to Lisbon in July 1998 on the occasion of the
first informal US-EU Drugs Forum.
As regards Latin America, the Centre contributed to the preparatory process of the
‘Coordination and cooperation mechanism between the European Union, Latin
America and the Caribbean — Comprehensive action plan on drugs’ which was for-
mally adopted at the European Union, Latin America and Caribbean Summit in Rio
de Janeiro in June. In preparation for this event, the Centre published the proceed-
ings of the October 1998 Euro-Ibero American Seminar: Cooperation on drugs and
drug addiction policies and its final statement, the ‘Declaration of Oporto’ (8).
No picture of 1999 could be complete without reference to the numerous visits paid
to the Centre by many who have demonstrated sensitivity and commitment over the
years to addressing the drugs problem. It was a considerable honour for me to
receive an array of dignitaries from Heads of State to government representatives,
ambassadors, parliamentarians and national drug coordinators. I also welcomed
many scientists, researchers, experts and grassroots practitioners in the drugs field,
all of whom make such a valuable contribution to the Centre’s work.
In February, their Excellencies Presidents Jacques Chirac of France and Jorge
Sampaio of Portugal visited the EMCDDA and pronounced statements on the impor-
tance of ‘objective, reliable and comparable information’ on drugs. President Chirac
reiterated the ‘vital importance’ of the EMCDDA in developing the ‘required 
knowledge-base for sound judgements’, while President Sampaio complimented the
EMCDDA’s initiatives ‘that are so crucial to political decision-making’. ‘We need to
know more to make better decisions’, he said. In November, King Albert II of the
Belgians and Queen Paola visited the Centre accompanied by President Jorge
Sampaio and the First Lady of Portugal. During this royal and presidential visit, His
Majesty King Albert applauded the fact that, thanks to the EMCDDA, EU Member
States could now assess their national drugs situation in relation to that of other EU
countries and obtain a Europe-wide picture of the phenomenon.
Although the scope of the agency’s activities in 1999 is, of course, too vast to cover
in depth here, I trust that this overview provides a flavour of the EMCDDA’s achieve-
ments during the year and describes the backdrop against which its individual activ-
ities were undertaken. The Centre operated in 1999 with a budget of EUR 8 250 000
and, by the end of the year, employed 51 statutory staff members. The recognition
that the Centre’s work received in 1999 contributed greatly to increasing its visibility
among its target audiences and I take this opportunity to thank all those who
(8) Promoted by the President of the Portuguese Republic and organised under the patronage of the Vice-
President of the European Commission in cooperation with the Portuguese government and with the
support of the EMCDDA (8 and 9 October 1998, Porto, Portugal). 
contributed to the results achieved. Much attention focused during the latter half of
the year on the evaluation of the Centre by external consultants, an exercise
designed to provide an in-depth analysis of the EMCDDA’s programmes and 
operations. The results of this procedure, which are due in spring 2000, are much
awaited and are expected to play a constructive role in the further development of
our work and procedures in the years to come.
Georges Estievenart
Executive Director, EMCDDA
January 2000
11
Introduction  
12
Priority areas as listed in annex
to the EMCDDA founding
Regulation (EEC) No 302/93
Priority area 1: Demand and
reduction of the demand for drugs
Consolidating and enhancing
achievements
Priority area 2: National and
Community strategies and policies
(with special emphasis on 
international, bilateral and
Community policies, action plans,
legislation, activities and 
agreements)
Developing achievements
Tasks as listed in Article 2 of the
EMCDDA founding regulation
A. Collection and analysis
of existing data
B. Improvement of data-comparison
methods
C. Dissemination of data
D. Cooperation with European and
international bodies and organi-
sations and with non-Community
countries
A. Collection and analysis of 
existing data
Priority objectives as listed in the EMCDDA
1998–2000 work programme
Priority objective 1
Consolidating and improving the Centre’s 
epidemiological and demand-reduction information
systems on the basis of agreed sets of core data
(a) Current trends and patterns: monitoring traditional
illicit drugs
(b) New trends: setting up and developing a mechanism
for the information exchange, risk assessment and
control of new synthetic drugs
Priority objective 2
Consolidating and enhancing the Reitox network in
accordance with the decisions taken by the 
EMCDDA Management Board
Priority objective 3
Improving and developing reliable and comparable
methods, data systems and key indicators
Priority objective 4
Improving the quality of the Annual report on the
state of the drugs problem in the European Union,
the visibility of the work of the EMCDDA and the
Reitox network and the dissemination of the infor-
mation collected and produced by the EMCDDA
Priority objective 5
Developing structured cooperation with the
EMCDDA’s international partners and ensuring
synergies and complementarity with EU pro-
grammes and activities, avoiding any duplication
of work
Priority objective 6
Developing tools and methodologies for comparing
interventions, legislation, strategies and policies in
the EU (including cost-effectiveness evaluation)
EMCDDA 1998–2000 work
programme
Chapter 1
Epidemiology
In 1999, the EMCDDA’s work in the field of epidemiology focused on the
collection and analysis of existing data and on the improvement of data-
comparison methods, in relation to priority objectives 1, 2, and 3 of the
1998–2000 work programme. 
Major tasks included: synthesising epidemiological information for the
EMCDDA’s Annual report on the state of the drugs problem in the 
European Union 1999; developing tools and expert networks for carrying
out more in-depth and policy-related data analysis and tracking and
understanding emerging trends; developing five comparable key
indicators of drug use and major health consequences in the EU; 
finalising a range of project reports; and cooperating with other
institutions under priority objective 5.
14
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1998–2000 work programme
Epidemiology, activities in 1999
Priority objective 1
Consolidating and improving the Centre’s epidemiological and demand-
reduction information systems on the basis of agreed sets of core data
(a) Current trends and patterns: monitoring traditional illicit drugs
Epidemiological information systems
Priority objective 2
Consolidating and enhancing the Reitox network in accordance with the deci-
sions taken by the EMCDDA Management Board
Reitox support projects (9)
Priority objective 3
Improving and developing reliable and comparable methods, data systems and
key indicators
Epidemiological key indicators
Priority objective 5
Developing structured cooperation with the EMCDDA’s international partners
and ensuring synergies and complementarity with EU programmes and activi-
ties, avoiding any duplication of work
Cooperation in the field of epidemiology
Epidemiological information systems
In 1999, the EMCDDA’s work in this area included: collecting and synthesising data
for the 1999 Annual report; strengthening expert networks to improve the collec-
tion, exchange and dissemination of both qualitative and quantitative information;
and carrying out a range of projects to increase policy relevance through data 
analysis (including a study to improve data quality).
Collecting and analysing data for decision-makers
In 1999, the Centre worked on a number of projects to develop and apply tools for
the collection and analysis of drug-use data. These are outlined below.
Data collection and analysis for the EMCDDA’s 1999 Annual report
Data collection and registration
Epidemiological data were collected from the national focal points (NFPs) using
standard tables which were carefully checked and entered into databases. The data
(9) Formerly Reitox ‘specific projects’. For full description see Chapter 3.
were supplemented by information from published research and studies undertaken
by the EMCDDA.
Synthesis and analysis of data
The abovementioned statistical data were analysed by the Centre, along with the
Reitox national reports (10) and supplementary information from EMCDDA studies
and the wider scientific literature. These data, once synthesised, contributed to the
1999 Annual report, in particular to Chapter 2 (Prevalence, patterns and conse-
quences of drug use), but also Chapter 1 (Developments in drug use, problems and
responses) and parts of Chapter 3 (Established responses to drug misuse in the EU)
namely: ‘Cannabis: trends and responses’ and ‘Synthetic drugs: developments and
responses’.
Emerging trends in drug use and qualitative research on drug-use patterns
Emerging trends in drug use
Following a feasibility study completed in 1998, ‘Identifying, tracking and under-
standing emerging trends in drug use’, three expert meetings were held in 1999 to
explore its recommendations. The first meeting in October, involving ‘frontline’ drug
workers from key cities, aimed to synthesise information on drug-use trends and to
develop instruments for data collection. The second meeting in November looked
at systems for testing the contents of products on the illicit drug market and under-
standing patterns of consumption. The third meeting in December developed prac-
tical ideas on networking. Dissemination and feedback through a website bulletin
were also explored. A call for tender was launched in October for a feasibility study
on monitoring the youth media as an information source on emerging drug trends
(contractor: Gruppo Abele, Italy).
Qualitative research on drug-use patterns
In 1999, the Centre’s epidemiology department, in collaboration with its demand
reduction department, continued to coordinate and support a network of qualitative
researchers on drug-use patterns in the EU (see Chapter 2). Access to information on
such research improved during the year, thanks to the further development of a
website on the topic (http://www.qed.org.uk). A call for tender was launched in
October to maintain, update and develop the website over the next two years (con-
tractor: Jane Fountain, United Kingdom). An EMCDDA scientific monograph on
qualitative research (‘Understanding and responding to drug use: the role of quali-
tative research’) and a new EMCDDA Insights publication (‘Injecting drug use, risk
behaviour and qualitative research’) were under preparation at the end of the year.
Bibliographic files with thorough documentation on European qualitative research
on drugs — collected by EMCDDA projects conducted during 1996 to 1998 on this
topic — were imported into the database of the EMCDDA’s documentation centre.
Early-warning system on new synthetic drugs
In cooperation with the EMCDDA’s unit responsible for implementing the joint
action on new synthetic drugs (see Chapter 4), the Centre’s epidemiology depart-
ment collected and analysed epidemiological and social data on the new synthetic
drug 4-MTA (4-methylthioamphetamine). It also reviewed, together with the EMCDDA
15
(10) National reports produced by the national focal points (as one of the Reitox core tasks) describe the
drug situation in an EU Member State and provide core data for the EMCDDA’s Annual report and other
analyses.
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Scientific Committee, risk-assessment guidelines for new synthetic drugs and
approaches to weighting criteria. In addition, the department participated in the
risk-assessment meeting on 4-MTA and in the preparation of a final risk-assessment
report on the substance (see Chapter 4).
Dynamic modelling of drug use, its spread, consequences and costs
Incidence of problem drug use and time trends in indicators
The final report of a pilot study funded under the Centre’s 1998 budget to analyse
the incidence of problem drug use in four European cities was submitted to the
EMCDDA in March. The study estimated the latency time between first drug use and
first demand for treatment and examined factors affecting this period. The informa-
tion collected was used to determine trends in incidence. Results from Amsterdam,
London and Rome suggested that, on average, the delay before first treatment is long
(5–7 years), but even longer in younger users, which may have significant implica-
tions for treatment services. Methodological issues were identified but will require
further investigation in 2000 (contractor: University Tor Vergata, Italy).
Study on the incidence of problem drug use and the latency time to treatment
in the European Union
In the context of the above, a new study was launched in December to improve
methodological understanding of the issues of incidence and latency and to explore
further sites. This study will build on the analyses carried out during the pilot study
by paying particular attention to: comparability between sites; sources of error;
problems of the back-calculation method; and interpretation of differences between
sites and over time, including the effect of treatment availability (contractor:
University Tor Vergata, Italy). 
Geographical spread of drug use
The results of a pilot study, funded under the 1998 budget to apply geographical
information systems (GIS) to drug data, were submitted to the EMCDDA in April.
Goals outlined for the future were to develop an explanatory model, database and
maps showing geographical diffusion of drug use and spatial distribution of indica-
tors in the EU. Maps were developed showing both temporal and spatial diffusion
of drug use in the west of Scotland from 1980 to 2000. At European level, GIS were
used to display prevalence estimates of problem drug use and hepatitis in injecting
drug users (IDUs). English and Italian regional examples revealed how mapping
data requires careful interpretation. Italian data showed how the heroin epidemic in
the 1990s later resulted in treatment demand following major trafficking routes
(contractor: University of Keele, United Kingdom).
Research networks on modelling temporal and geographic spread
Funding from the European Commission’s targeted socioeconomic research (TSER)
programme (Directorate-General for Research) in 1999 enabled the Centre to estab-
lish two networks of researchers to estimate the diffusion of problem drug use using
dynamic models. (These are part of a larger network on statistical and dynamic
modelling which aims to: promote information exchange on new methods; improve
the policy relevance of modelling; stimulate scientific publications; and develop
proposals for in-depth studies.) The first of the two networks focuses on incidence
and time trends in problem drug use, and the second on mapping and modelling
the geographic spread of drug use. Two working-group meetings were held in
December 1998 and June 1999, while a coordination meeting of the larger model-
ling network was held in Lisbon in September (coordinators: University Tor Vergata,
Italy, and University of Keele, United Kingdom).
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Impact and costs of hepatitis and HIV in injecting drug users in the EU
The final report of a pilot study, funded under the 1998 budget to estimate the
impact and costs of hepatitis B/C and HIV infection in injecting drug users in the EU,
was submitted to the EMCDDA in November. A series of papers on the topic were
also prepared and discussed at an expert meeting held in Bilthoven (the
Netherlands) in June. In addition, the project produced an overview of modelling
approaches and methods for economic assessments, including indirect and social
costs, for estimating costs of drug use in general (contractor: National Institute of
Public Health and the Environment/RIVM, the Netherlands).
Macroeconomic analysis of heroin markets in the EU and the impact of 
substitution treatment
A call for tender was launched in October regarding a project to: develop a macro-
economic model of heroin markets; test it with available data on consumption and
consumption patterns; and analyse the possible effects of substitution treatment on
price, consumption, consequences and heroin supply in the EU. The model should
also lay a basis for examining the relative impact of other interventions (e.g. law
enforcement) on the heroin market (contractor: Modus Vivendi, Belgium).
Research network on modelling costs of drug use and cost-effectiveness of 
interventions
Funding from the European Commission’s TSER programme enabled the Centre to
establish a network of researchers to estimate the costs of problem drug use and the
cost-effectiveness of interventions using dynamic models, as part of the larger net-
work on statistical and dynamic modelling (see above). The network on costs con-
sists of three working groups on: epidemiological and social issues; dynamic mod-
elling; and economic issues (contractor: National Institute of Public Health and the
Environment/RIVM, the Netherlands).
Research network on economic analyses of drug markets and responses
Also with funding from the TSER programme, the EMCDDA created a working
group for the analysis of drug markets using dynamic models, as part of the larger
network on statistical and dynamic modelling. A literature review was compiled
during 1999 and work in 2000 will aim to model the actors and mechanisms of drug
markets at different levels. The working group is closely connected with two other
studies on: local drug markets and drug availability; and macroeconomic analysis
of heroin markets in the EU and the impact of substitution treatment. The group was
also represented in the coordination meeting in Lisbon in September of the wider
modelling network (contractor: University of York, United Kingdom).
Drugs and social exclusion, focusing on minorities
Following a workshop on ‘Drugs, social exclusion, migration and minorities’ held at
the EMCDDA in December 1998, a study to map available information in the EU
on social exclusion and drugs, with a particular focus on minorities, began in 1999.
This project will clarify concepts and definitions, and review, analyse and critically
assess available information. It will also analyse relationships between social exclu-
sion, minorities and drugs and identify key issues (contractors: Reitox national focal
point, United Kingdom and University of Middlesex, United Kingdom).
17
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Local drug markets and drug availability
Local drug markets and drug availability are both the determinants and conse-
quences of drug use and interact with drug demand and with responses to it at local
level. The EMCDDA embarked on a pilot project in September studying local drug
markets in Frankfurt and Milan. The first phase of the project focuses on conceptual
and descriptive approaches of drug markets (actors, mechanisms, etc.), their conse-
quences and public responses. The study is expected to lead to an analysis of dif-
ferent policy options (contractor: Max-Planck Institute, Germany).
Law-enforcement statistics as epidemiological indicators
The reliability and comparability of law-enforcement statistics (e.g. arrests) is
unknown, and their value as indirect indicators of drug trends is unclear. An exam-
ination of law-enforcement data sources in three countries (France, Portugal and the
United Kingdom) was initiated by the EMCDDA in August to gain an insight into the
context, recording practices and methodological characteristics of available law-
enforcement data. An expert brainstorming workshop was held in December to dis-
cuss data comparability and reliability at EU level, and the use of law-enforcement
statistics in an epidemiological framework.
Reviews of drug-traffic accidents and non-fatal emergencies
The Centre completed two literature reviews in 1999. The first focused on drug use,
impaired driving and traffic accidents, which led to a report and bibliography of 700
scientific publications, accessible via the Internet (contractor: Reitox national focal
point, Ireland). The second looked at information on drug-related non-fatal 
emergencies and led to a report and an annotated bibliography on the subject 
(contractor: Institut Municipal d’Investigació Mèdica, Spain).
Quality assurance of epidemiological data
An evaluation of the quality of epidemiological data submitted to the EMCDDA by
the national focal points was completed in May (contractor: Reitox national focal
point, Austria).
Reitox support projects
Following a decision of the EMCDDA Management Board that facilitating the imple-
mentation of five key epidemiological indicators should be a core task for the Reitox
national focal points (see Chapter 3), the epidemiology department asked the NFPs
to draw up work plans taking into account national circumstances and to provide
initial progress reports. Progress in implementing the indicators will be monitored
by the epidemiology department through regular follow-up. With regard to specific
indicators, and building on work carried out under the 1998 Reitox work pro-
gramme, the epidemiology department contributed to developing, testing and
implementing standards on indicators of treatment demand and drug-related deaths,
as well as to supporting the development of national prevalence estimates in order
to improve their comparability.
Epidemiological key indicators
In 1999, the department focused on promoting the development and subsequent
implementation of instruments and standards relating to five key epidemiological
indicators by undertaking the following projects.
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Drug use in the general population
Creation of a European Union databank of population surveys on drug use
and a joint analysis of data collected
A call for tender was launched in October to set up a European databank of national
population surveys on drug use in the EU Member States and to conduct a joint
analysis of these data. The aim of the project is to draw up a comparative overview
of drug-use prevalence and associated factors in the general population, using the
variables and categories defined in the standard instruments produced by the
EMCDDA for population surveys. The project will assess the methodological prob-
lems of such an overview, evaluate and develop the EMCDDA’s standards, and pro-
duce proposals for new methodological studies (contractor: Quinx Research, the
Netherlands).
Preparation of a European manual on general population surveys on drug
use
The objective of this project, launched at the end of 1999, will be to present, in a
consistent and accessible form, the results of studies carried out by the EMCDDA in
this area since 1996. It will assess and improve the quality and comparability of
national surveys on drug use, including a standard set of common core items the
‘European model questionnaire’ (contractor: Quinx Research, the Netherlands).
Prevalence estimates of problem drug use
Project on the implementation of methods for estimating national preva-
lence of problem drug use in the EU Member States
Previous projects related to this indicator tested six methods for estimating the
prevalence of problem drug use in the EU Member States. The 1999 project devel-
oped this work by: coordinating peer reviews and updating national estimates for
the 1999 EMCDDA Annual report; coordinating work to improve methodology; and
developing guidelines and providing advice to aid comparable implementation in
the Member States (contractor: Reitox national focal point, Germany).
Feasibility study on the implementation of longitudinal studies on chang-
ing patterns of use, health risks, careers and needs in young problem drug
users
A call for tender was launched in September for a project to assess the feasibility of
setting up comparative longitudinal studies of young, out-of-treatment drug users.
This initiative is important to complement global prevalence estimates and data
from known drug users regarding drug-use patterns, careers, health risks and health-
care needs. The project will review ongoing and planned studies in the EU, com-
pare available data and instruments, and aim to develop a common approach lead-
ing, if possible, to a research proposal for a collaborative EU study in 2000 (con-
tractor: Reitox national focal point, the Netherlands).
Research network on national and local prevalence estimation
With funding from the European Commission’s TSER programme, the Centre created
two networks for estimating the prevalence of problem drug use using dynamic
models, as part of the larger expert network on statistical and dynamic modelling.
The first network concentrates on prevalence estimation at national level and the
second on estimates at the local level. Two meetings were held in March and May,
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and the coordinators attended a coordination meeting of the wider modelling net-
work in Lisbon in September (coordinators: Reitox focal point, Germany and the
University of Glasgow, United Kingdom).
Demand for treatment by drug users
Field trial of data collection
This project, funded under the 1998 budget and undertaken in cooperation with the
Council of Europe’s Pompidou Group, produced a draft European protocol for col-
lecting drug treatment data in April 1999. This built on previous studies of data
availability and comparability in the Member States. The project field-tested the
draft protocol in all EU countries during the spring and summer. An EMCDDA
expert group on treatment demand, nominated by national focal points to partici-
pate in this project, met in October in Lisbon to discuss the results, purposes and
uses of treatment information and to explore future perspectives. The draft protocol
is expected to lead to a formal joint EMCDDA-Pompidou Group protocol to be pub-
lished in the first half of 2000 (contractor: Reitox national focal point, Germany).
Coordinating implementation of the EMCDDA-Pompidou Group standard
protocol on the treatment demand indicator in the EU Member States, 
collection and analysis of information on treatment demand
Building on results of the abovementioned field trial, the German national focal
point was contracted to coordinate the initial process of implementation of the
EMCDDA-Pompidou Group standard protocol on treatment demand information in
the EU Member States. Implementation began with an analysis of work plans from
the national focal points and the development of a timetable for tasks to be carried
out in the Member States. The joint protocol will be published by the EMCDDA in
2000 (contractor: Reitox national focal point, Germany).
Drug-related deaths and mortality among drug users
Test of the draft standards developed by EMCDDA projects on drug-
related deaths, and developments of proposals to improve data quality 
and comparability
Building on previous studies, standard guidelines for data collection on drug-related
deaths were drawn up in May, coordinated by the Dutch national focal point and
involving Eurostat and information exchange with the World Health Organisation
(WHO). Focal points identified national experts, and data were collected in most
Member States, following the EMCDDA guidelines for general mortality registries
(GMR) and special registries (SR). An EMCDDA expert group on drug-related death
statistics met in Lisbon in November to discuss the results of data collection and
methodological problems. An ad hoc expert group was convened in July to consider
guidelines for coding drug-related deaths using the 10th edition of the international
classification of diseases (ICD-10) (contractor: Reitox national focal point, 
the Netherlands).
Coordinating implementation of the EMCDDA standard guidelines on the
drug-related death indicator in the EU Member States, collection and
analysis of information on drug-related deaths
In December, the EMCDDA commissioned the Dutch national focal point to 
coordinate work on implementing the EU standard guidelines on statistics on drug-
related deaths, including methodological studies of data quality and comparability.
20
General report of activities 1999
Collaboration with Eurostat and the WHO will continue, especially in relation to the
guidelines for the 10th edition of the international classification of diseases (ICD-
10). In addition, the project will collect and analyse existing information on drug-
related deaths in the Member States to produce a European overview of drug mor-
tality (contractor: Reitox national focal point, the Netherlands).
Coordinating implementation, follow-up and analysis of cohort studies on
mortality among drug users in European Union Member States
Previous EMCDDA projects conducted during 1997 and 1998 produced a common
protocol for mortality cohort studies and promoted the establishment of new cohorts
in several countries. Most participants started or continued enrolment and follow-
up of these cohorts. A basic retrospective analysis of most cohorts was carried out
in the framework of this project, and results were reported in a meeting held in
Rome in September (contractor: Osservatorio Epidemiologico Regione Lazio, Italy).
Mortality of drug users in the EU: coordinating implementation of new
cohort studies, follow-up and analysis of existing cohorts and development
of new methods and outputs
A new project started at the end of 1999 to expand and continue the work of pre-
vious projects. The objectives are to: coordinate follow-up and analysis of existing
cohorts; implement new cohorts in new sites; develop methodologies to measure
outcomes other than mortality; and assess the influence of factors such as the type
of treatment interventions. The methodological guidelines for mortality cohort stud-
ies produced in previous projects will be published by the EMCDDA in 2000 
(contractor: Osservatorio Epidemiologico Regione Lazio, Italy).
Infectious diseases among injecting drug users (IDUs)
Improving data quality for surveillance
The final report of a project, funded under the 1998 budget on improving data qual-
ity for the surveillance of hepatitis B/C and HIV infection in injecting drug users, was
received by the EMCDDA in November. An expert meeting was held in July in
Glasgow to discuss possible options for surveillance. The project evaluated avail-
able data in all EU Member States and drew up recommendations to improve data
for monitoring the spread of infectious diseases in injecting drug users using com-
parable methods and definitions (contractor: University of Glasgow, United
Kingdom).
Project to improve collection of data on the key indicator ‘hepatitis B and
C and HIV in injecting drug users’
As a follow-up to the above project, a new project began in December to start
implementing the recommendations at the national level through the Reitox nation-
al focal points. The tasks of the project during the first phase are to: define the tasks
for work at national level and develop draft guidelines; assist the NFPs in identify-
ing key institutions, experts and data sources; assist in the formulation of national
work plans and analysis of the data; and to improve the EMCDDA standard tables
for collection of existing data (contractors: Scottish Centre for Infection and
Environmental Health/SCIEH, United Kingdom).
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Cooperation in the field of epidemiology
Working with European and international partners
In the field of epidemiology, cooperation was fostered throughout 1999 with a range
of partners, including: services of the European Commission (Directorate-General
for Research, Eurostat, health monitoring programme, etc.); the United Nations
International Drug Control Programme (UNDCP); the Pompidou Group of the
Council of Europe; Europol; EuroHIV (formerly the European Centre for the
Epidemiological Monitoring of AIDS); Unaids; the US National Institute on Drug
Abuse (NIDA); the United States White House Office of National Drug Control
Policy (ONDCP); and the International Epidemiology Work Group (IEWG).
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Reports and output of projects, 1999
Epidemiology
Collecting and analysing data for decision-makers
Dynamic modelling of drug use, its spread, consequences and costs
• ‘Pilot project to estimate time trends and incidence of problem drug use in
the European Union’
• ‘Pilot project to develop a model of geographical spread of drug misuse in
the European Union’
• ‘First six-month progress report of the TSER-network on drug-use modelling’
• ‘Project to analyse impact and costs of hepatitis B/C and HIV infection in
injecting drug users in the EU’
• ‘First 12-month progress report of the TSER-network on drug-use modelling’
Qualitative research on drug use patterns
Qualitative research website (http://www.qed.org.uk)
Epidemiological key indicators
Prevalence estimates of problem drug use
• ‘Methodological guidelines to estimate the prevalence of problem drug use
on the local level’
• ‘Scientific review of the literature on estimating the prevalence of drug mis-
use on the local level’
• ‘Study to obtain comparable national estimates of problem drug-use preva-
lence for all EU Member States’
• ‘Methodological guidelines for estimating problem drug-use prevalence on
the national level’
Demand for treatment by drug users
• ‘The DRD Standard. Guidelines and protocols for extracting data on drug-
related deaths from the registries of the Member States of the European
Union. Version 1.0’
• ‘Field trial of implementation of a standard protocol to collect information on
treatment demand in the EU Member States’
Drug-related deaths and mortality among drug users
• ‘The Treatment Demand Indicator (TDI). Standard Protocol 1.1’
• ‘Coordination of implementation, follow-up and analysis of cohort studies
on mortality among drug users in European Union Member States’
• ‘Testing draft standards developed by EMCDDA projects on drug-related
deaths and developing proposals to improve data quality and comparability’
Infectious diseases among injecting drug users (IDUs)
• ‘Project to improve data quality for surveillance of hepatitis B/C and HIV
infection in injecting drug users in the EU’
Other projects
• ‘Literature review on the relation between drug use, impaired driving and
traffic accidents’
• ‘Evaluation of the quality of epidemiological information provided to the
EMCDDA’ (information maps and national reports)
• ‘Literature review and synthesis of scientific literature on drug-related non-
fatal emergencies’
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Major meetings organised by the EMCDDA, 1999
Epidemiology
Date Place Event
4–5 February Munich EMCDDA-German focal point project steering
group meeting: field trial to implement a stan-
dard protocol to collect information on treat-
ment demand in the EU Member States
15 February Rome EMCDDA-Osservatorio Epidemiologico expert
meeting: project on cohort studies on mortality
of drug users
11–12 March EMCDDA EMCDDA-German focal point expert meeting:
national prevalence estimates of drug addiction 
16–17 March Amsterdam EMCDDA meetings with drug-information ser-
Rotterdam vices: detecting, tracking and understanding
Utrecht emerging trends in drug use
7–8 May Amsterdam EMCDDA-Dutch focal point expert meeting:
developing instruments and guidelines to
improve quality and comparability of general
population surveys on drugs in the EU
20–21 May Maynooth EMCDDA-University of Glasgow expert meeting:
(Ireland) prevalence of problem drug use at local level
(in the framework of the TSER-funded European
network to develop policy-relevant models and
socioeconomic analyses of drug use, conse-
quences and interventions)
24–25 June Bilthoven EMCDDA-Dutch focal point/RIVM/University
Tor Vergata expert meeting: impact and costs of
hepatitis B/C and HIV in IDUs in the EU
28 June Bilthoven EMCDDA-University Tor Vergata expert meet-
ing: time trends and incidence of problem drug
use (TSER-funded as above)
2 July Utrecht EMCDDA-Dutch focal point expert meeting:
drug-related deaths (testing the draft standards
developed by the EMCDDA on drug-related
deaths, and developing proposals to improve
data quality and comparability)
12–13 July Glasgow EMCDDA-University of Glasgow/SCIEH expert
meeting: project to improve data quality for the
surveillance of hepatitis B/C and HIV infection
in IDUs in the EU
19 July Munich EMCDDA-German focal point expert meeting:
field trial to implement a standard protocol to
collect information on treatment demand in the
EU Member States
16–17 EMCDDA Coordinators meeting: European network to
September develop policy-relevant models and socio-
economic analyses of drug use, consequences
and interventions
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27–28 Rome EMCDDA-Osservatorio Epidemiologico expert
September meeting: coordinating the implementation, 
follow-up and analysis of cohort studies on
mortality among drug users in the EU Member
States
13 October London EMCDDA-University of Middlesex: project
meeting on drugs and social exclusion, focusing
on minorities
18–19 October EMCDDA EMCDDA expert group meeting: treatment
demand indicator 
22 October EMCDDA EMCDDA expert (front-line) drug workers’
meeting: collecting timely information on
emerging trends
8–9 November EMCDDA EMCDDA expert group meeting: drug-related
deaths
29 November Vienna EMCDDA national focal points meeting: drug
market products
8 December Paris EMCDDA national focal points meeting: explor-
ing systematic methods for collecting and
analysing information collected from targeted
networks/panels of key individuals in Europe
9 December EMCDDA EMCDDA-Max Planck Institute project meet-
ing: local drug markets
13–14 December EMCDDA EMCDDA expert meeting: law enforcement
indicators
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Major meetings attended by the EMCDDA, 1999
Epidemiology
Date Place Event
19 January Vienna UNDCP-EMCDDA meeting: examining oppor-
tunities for collaboration
29 January Barcelona Lecture on drugs epidemiology, postgraduate
programme ‘Master en toxicodependencias’,
University of Barcelona
10–12 March Berne International symposium: heroin-assisted
treatment for dependent drug users — state of
the art and new research perspectives,
University of Berne
21–25 March Geneva 10th international conference on the reduc-
tion of drug-related harm, International Harm
Reduction Association
19–21 April Strasbourg Seminar on road traffic and illicit drugs,
Pompidou Group 
28–30 April Strasbourg 43rd meeting of the permanent correspon-
dents of the Pompidou Group of the Council
of Europe (see Chapter 8)
28–30 April Brussels European socio-economic research confer-
ence, European Commission
4 May Luxembourg Fifth meeting of the Committee for the 
programme of Community action on health
monitoring, European Commission
28–29 May Milan Third European seminar on HIV and hepatitis
in prison, European network for AIDS and
hepatitis in prisons, European Commission,
WHO, German medical association
2–3 June Vienna Inter-sessional working group of the Com-
mission on Narcotic Drugs (CND), UNDCP
7–8 June Strasbourg 29th meeting of the experts in epidemiology of
drug problems of the Pompidou Group
9–11 June Vancouver Sixth meeting of the International Epide-
miology Work Group on drugs (IEWG)
Parallel meeting of the National Institute of
Drug Abuse (NIDA); Community Epide-
miology Work Group (CEWG) and Canadian
Community Epidemiology Network on Drug
Use (CCENDU)
26–28 August Atlanta Second annual meeting of the global research
network on HIV prevention in drug-using 
populations, NIDA
29 August Atlanta HIV prevention conference, Centre for Disease
1 September Control
30 August Florence 15th International Epidemiological Asso-
ciation (IEA) international scientific meeting
on ‘epidemiology for sustainable health’,
satellite seminar on the ‘epidemiology of drug
use’.
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1–2 September Århus European summer school on comparative
social research on drugs and drug policy, com-
parative analysis of drug use, Nordic Council
for Alcohol and Drug Abuse
20–21 September Vienna Global programme on assessing the magni-
tude of drug abuse — practice, measures and
resources, UNDCP
20–22 September Vienna 10th annual conference on drug use and pol-
icy of the European Society for Social Drug
Research 
28–29 September Vienna Second inter-sessional working group to draft
guidelines to facilitate reporting on the imple-
mentation of the global programme of action,
UNDCP
14–15 October The Hague EMCDDA-Europol meeting: memorandum of
understanding
19 October Madrid Fifth Conferencia nacional sobre SIDA y dro-
gas, Plan Nacional sobre el SIDA and the Plan
Nacional sobre Drogas, Spain
3–5 November Viña del Mar International seminar on drug information sys-
(Chile) tems: purposes, components and methodolo-
gies, Consejo Nacional para el Control de
Estupefacientes
5–7 November Naples Fourth general meeting on drugs and HIV,
ways of assumption, risks, prevention strate-
gies, Change
10–12 November Amsterdam First international conference on nightlife,
substance use and related health issues, Dutch
focal point and John Moores University,
Liverpool 
11–13 November Berlin Workshop on HIV surveillance in hard-to-
reach populations, Unaids
29–30 November London Fourth international hepatitis C conference,
Mainliners
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Articles published, 1999
Epidemiology
Houweling, H., Wiessing, L. G., Termorshuizen, F., Hamers, F., Gill, O. N. and
Sprenger, M. J. W., ‘An age-period-cohort analysis of 50 875 AIDS cases among
injecting drug users in Europe’ in International Journal of Epidemiology,
December 1999; 28: 1141–1148.
Simon, R., Donmall, M., Hartnoll, R., Kokkevi, A., Ouwehand, A. W.,
Stauffacher, M. and Vicente, J., ‘The EMCDDA/Pompidou Group treatment
demand indicator protocol: A European core item set for treatment monitoring
and reporting’ in European Addiction Research 1999; 5: 197–207.
Vicente, J., ‘Evaluación de la situación de drogas: necesidad de una estrategia
de información integrada y rigurosa’ (Evaluation of the drug situation: the need
for a comprehensive and rigorous information strategy) (Editorial) in Gazeta
Sanitaria 1999; 13: 79–81.
Wiessing, L. G., Hartnoll, R. L., Houweling, H., Jager, J. C., Downs, A. M. and
Hamers, F. F., ‘Impact and control of AIDS, HIV and hepatitis B and C among
injection drug users in Europe: an exploratory overview’ in Global Research
Network Meeting on HIV Prevention in Drug-Using Populations, Geneva, 
25–26 June 1998, Inaugural Meeting Report. National Institute on Drug Abuse
— National Institutes of Health — US Department of Health and Human
Services, 1999.
Wiessing, L. G., Houweling, H., Sandfort, Th. G. M., Schop, W., van den
Akker, R. and Hoogenveen, R. T., ‘Reaching homosexual men for HIV surveil-
lance through a gay magazine’ in European Journal of Epidemiology 1999; 15:
429–437.
Wiessing, L. G., van Roosmalen, M. S., Koedijk, P., Bieleman, B. and
Houweling, H., ‘Silicones, hormones and HIV in transgender street prostitutes’
(letter) in AIDS 1999; 13: 2315–2316.
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Demand reduction
In 1999, the EMCDDA’s work in the field of drug demand reduction
corresponded primarily to priority objectives 1, 2, 3 and 5 of the 1998–2000
work programme. The main emphasis was placed on the further
development of the Centre’s Internet-based information systems on
demand-reduction initiatives as well as on the promotion of the evaluation
of these activities through the development of specific tools and training
events. A major event of the year was the second European Conference on
the Evaluation of Drug Prevention, co-organised with the European
Commission in Strasbourg in December. Furthermore, the EMCDDA
strengthened the concept of evaluation highlighted in the new European
Union drugs strategy (2000–04), approved at the Helsinki European Summit
in December.
During the year, the Centre invested in expanding and consolidating the
Reitox focal points’ national networks in the area of demand reduction in
order to improve the quality and the quantity of information gathered in
this domain. It also finalised a study on the state of the art of substitution
treatment with the collaboration of experts from each EU Member State.
Finally, through participation in national and regional meetings, the Centre
succeeded in raising the profile of its demand-reduction activities, which
are increasingly recognised both by policy-makers and practitioners in the
drugs field.
1998–2000 work programme
Demand reduction, activities in 1999
Priority objective 1
Consolidating and improving the Centre’s epidemiological and demand-
reduction information systems on the basis of agreed sets of core data
(a) Current trends and patterns: monitoring traditional illicit drugs
Demand-reduction information systems
(b) New trends: setting up and developing a mechanism for the information
exchange, risk assessment and control of new synthetic drugs
Demand-reduction responses to new trends in synthetic drugs
Priority objective 2
Consolidating and enhancing the Reitox network in accordance with the 
decisions taken by the EMCDDA Management Board
Reitox project on networking in the field of drug demand reduction
Priority objective 3
Improving and developing reliable and comparable methods, data systems and
key indicators
Demand-reduction evaluation guidelines and instruments
Priority objective 5
Developing structured cooperation with the EMCDDA’s international partners
and ensuring synergies and complementarity with EU programmes and 
activities, avoiding any duplication of work    
Cooperation in the field of demand reduction
Other activities
Exploratory studies in the field of drug demand reduction
Demand-reduction information systems
Updating comprehensive demand-reduction data on drugs
During the first half of the year, the demand reduction department analysed infor-
mation submitted by the national focal points for inclusion in the Annual report on
the state of the drugs problem in the European Union 1999. This information was
provided in the form of national reports on the state of the drugs problem in each
EU country (see Chapter 3 and footnote 10) and via the EDDRA information system
on demand-reduction activities (see below).
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Exchange on drug demand-reduction action (EDDRA)
Thanks to a decision taken in 1998 to render implementation of the EDDRA data-
base a Reitox core task (see Chapter 3), significant progress was made in 1999 in
developing this project Europe-wide. A first step was to update the technological
features of the database in order to allow quick consultation and search possibili-
ties. A new dynamic multilingual facility was also finalised in June allowing navi-
gation in English, French and German.
In order to facilitate data collection on demand reduction in the EU Member States,
while at the same time ensuring security, an EDDRA off-line editing software pack-
age was released in November. This software may now be offered by national
‘EDDRA managers’ (based at the national focal points and responsible for inputting
country data into the system) to local project editors, offering them the possibility of
on-screen editing.
EDDRA was rendered year 2000 (Y2K) compliant during the year and important
technical improvements were made (contractor: Reitox national focal point,
Luxembourg). The number of projects carried by EDDRA increased in 1999 to 150
and the managers committed to doubling this number by the end of 2000. The basis
of a 2000 work plan was adopted by the national EDDRA managers in October. It
is foreseen that, in the future, EDDRA will also offer information on transnational
projects undertaken in the context of the EU’s Community action programme on the
prevention of drug dependence (1996–2000).
Information system on training activities (ISTRA)
In 1999, the EMCDDA launched a study into non-university vocational training in
demand reduction, complementing a 1998 study to compile an inventory of uni-
versity training facilities in the field (contractor: Reitox national focal point, the
Netherlands). The database resulting from this study is known as the information
system on training activities (ISTRA).
ISTRA offers information and data on training in the field of drug demand reduction
for students, teachers, planners and decision-makers in the European Union. The
database contains information on 103 training programmes and 74 institutes that
will be regularly updated and expanded to ensure maximum usefulness. For each
training programme entry, information is provided on: the contents, duration and
frequency of the programme; (e-mail) addresses of contact persons; selection 
criteria; and the substances addressed. In a second stage, the database will be 
accessible via the EMCDDA website (http://www.emcdda.org).
Demand-reduction responses to new trends in synthetic drugs
Study on demand-reduction activities related to synthetic drugs
In January 1999, the EMCDDA commissioned a study on ‘Demand-reduction 
activities in the field of synthetic drugs’, following up an earlier EMCDDA report on
the topic published in 1997 (11). The new study was completed in September 1999
and made available as a working document on the EMCDDA website (contractor:
Sozialpädagogisches Institut, Germany).
(11) EMCDDA Insights series No 1, New trends in synthetic drugs in the European Union: epidemiology and
demand-reduction responses, Lisbon: EMCDDA, 1997. ISBN 92-9168-030-3. See the following website
(http://www.emcdda.org/publications/publications.shtml).
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Information covering new and ongoing programmes in dance and ‘techno’ settings
was collected for the study via the snowball-sampling technique using faxed ques-
tionnaires to a variety of networks (12). Developments identified in this study as help-
ing to reduce the demand for synthetic drugs included: an increase in the number
of specific prevention projects; greater diversification of interventions; and progress
in evaluation or, at least, the perceived need for evaluation. The study also revealed
that the majority of interventions primarily continue to address drug-abstinent or
casual consumers rather than high-risk consumption groups, and that the majority
of activities still focus on information provision, regardless of the fact that scene-
oriented and personal-communication approaches might prove more effective.
Reitox project on networking 
in the field of drug demand reduction
The aim of this project was to: examine the advantages and disadvantages experi-
enced by networks already existing in the EU Member States; gauge the experience
gained from networking activities; and make recommendations on how networking
can be improved, rendered more efficient and further developed to the benefit of
the national focal points (contractors: Reitox national focal points, Spain, Ireland,
the Netherlands, Austria and Sweden). One observation made during the project
was that while networks were structures for facilitating cooperation, communication
and exchange with national partners, networking was seen as an ongoing and per-
manent process of communication and cooperation with these partners.
Demand-reduction evaluation guidelines and instruments
Guidelines for the evaluation of prevention
In May, the EMCDDA concluded a project on the ‘Implementation of the guidelines
for the evaluation of drug prevention’ (13) (contractors: Centro de Estudios sobre la
Promoción de la Salud/CEPS, Spain, and the Reitox national focal point, Germany).
The contractors distributed the guidelines to practitioners (largely by e-mail) and
collected and processed the annexed feedback sheets. This exercise allowed the
EMCDDA to trace the settings in which the guidelines were being used and to gauge
the utility of this evaluation tool based on results of in-depth interviews with pro-
fessionals. 
Most respondents commented that the guidelines assisted professionals and were
both effective and workable for the evaluation of prevention programmes. However,
the guidelines were regarded as rather demanding and requiring specific expertise
and training. The ultimate use of the evaluation guidelines will thus depend on
training and human and financial resources available to professionals.
(12) In this type of sampling, researchers orient themselves towards a target population, make contacts
and interview respondents. At the end of each interview, interviewees are asked to assist in identify-
ing new respondents. In this way, chains of respondents are created thus extending the sample. The
method is well suited to research in hidden populations.
(13) The guidelines were published in English in the EMCDDA Manuals series in 1998. They are available
as a working document in all 11 official EU languages.
Second European Conference on the Evaluation 
of Drug Prevention
The second European Conference on the Evaluation of Drug Prevention, entitled
‘Evaluation: a key tool for improving drug prevention’, organised by the EMCDDA
and the European Commission, was held from 2 to 4 December at the European
Parliament building in Strasbourg.
The conference assessed developments in the area of evaluation since the first
EMCDDA conference on the topic in March 1997 and promoted systematic evalu-
ation as a means of improving prevention practice. Some 150 participants involved
in the practical and strategic implementation of prevention evaluation in the EU, the
central and east European countries (CEECs) and third countries attended the event.
Conference sessions focused on how evaluation theory and knowledge can be
implemented into daily practice via evaluation tools and instruments such as those
developed by the EMCDDA (guidelines, evaluation instrument bank, EDDRA, etc.).
The conference adopted a set of recommendations aimed at facilitating and pro-
moting an ‘evaluation culture’ in drug-prevention programmes and strategies in the
EU Member States. These will be presented to the European Commission, giving it
the possibility to submit to the Council of the European Union draft recommenda-
tions on the evaluation of drug prevention.
Evaluation of outreach work
In October, the EMCDDA launched a follow-up project to an earlier study on
‘Outreach work among drug users in Europe’, published in the EMCDDA Insights
series in 1999 (see Chapter 5). The focus of the new study is to promote and
improve the evaluation of outreach work activities. Pressure to evaluate the effec-
tiveness of outreach work services calls for a greater degree of professionalism.
Outreach work requires a specific type of evaluation due to its specific target
groups, aims and interventions. As a result, existing EMCDDA evaluation tools will
need to be adapted and complemented with new instruments. The new project
therefore aims to: facilitate data-collection methods; develop evaluation guidelines
and tools; and enhance training and cooperation possibilities (contractor: Centre for
HIV/AIDS and Drugs Studies, United Kingdom).
Cooperation with the WHO and the UNDCP
in the field of the evaluation of treatment
In 1997, cooperation between the EMCDDA, the United Nations International Drug
Control Programme (UNDCP) and the World Health Organisation (WHO) began
with a project entitled the ‘Evaluation of the treatment of substance use disorders’.
The overall aim of the project is to increase the effectiveness, scope and impact of
information dissemination in the area of treatment evaluation.
The specific tasks of this ongoing project include developing, publishing and dis-
seminating training materials as a source of knowledge and guidance to policy-
makers, researchers and professionals. These materials take the form of work-
books on key aspects of the evaluation of substance abuse. The EMCDDA provides
technical and economic support for the preparation and testing of the workbooks.
Forty-five treatment centres throughout Europe participated in the project’s feasibil-
ity phase in 1999. This entailed filling in a ‘pre-workbook questionnaire’ designed
to collate data on the participant’s background, professional activities and expecta-
tions. The questionnaires sent to the Centre revealed a high degree of knowledge
and expertise in the field of treatment as well as a wide variety of activities under-
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way in this area. Replies were received from clinicians, programme-planners and
researchers as well as government planners and policy-makers. While respondents
generally appeared to have extensive knowledge on substance use disorders and
their treatment, they generally knew less about planning and implementing evalua-
tion. It is hoped, therefore, that the workbooks will be a step towards making eval-
uation activities routine. Follow-up is planned six months and one year after receiv-
ing the workbooks. In 1999, evaluation studies of treatment services in selected
European sites were underway with the support of the training materials.
Evaluation instrument bank
The evaluation instrument bank (EIB) project, launched in 1997 to report on exist-
ing instruments for evaluating drug prevention, was extended in 1999 to include
instruments for the evaluation of treatment (contractor: European Institute for the
Investigation of Risk Factors for Children and Adolescents/Irefrea, Spain). The EIB
was also further developed from a technical point of view (contractor: Reitox
national focal point, Luxembourg). The final version is scheduled for completion
early in 2000 and will be accessible on the EMCDDA’s website.
The EIB provides data and comment on evaluation instruments and their use as well
as on related studies, according to the specific case to be evaluated. It is designed
to be a flexible and expandable tool that allows the continuous inclusion of differ-
ent language versions of instruments or the adaptation of instruments to specific set-
tings. At the end of 1999, the EIB contained some 35 prevention evaluation instru-
ments and 150 treatment evaluation instruments (120 of the latter may be down-
loaded while 30 are copyright protected).
EDDRA and evaluation skills training
The Reitox national focal points, in cooperation with the EMCDDA, organised
national training courses in 1999 in order to commit professionals to the evaluation
of prevention and help them improve skills required to implement EDDRA. The
focal points selected and invited professionals from local or regional programmes,
targeting those with a peer-leader function. In 1999, training sessions were carried
out in Belgium, Germany, Greece, Spain, the Netherlands, Austria, Portugal and
Finland and involved approximately 1 000 participants. Training in the remaining
EU Member States will follow in 2000. Focal point representatives were satisfied
with the acceptance level of the training sessions as well as the increased visibility
they brought to the focal points themselves.
Cooperation in the field of demand reduction
Phare project on technical assistance to drug demand reduction
The EMCDDA continued to participate in the evaluation group of the Phare project
on technical assistance to drug demand reduction within the Phare multi-beneficiary
drugs programme. Following participation in meetings over two years and analysis
of the documents produced, the project was evaluated on the basis of the following
objectives: network strengthening; policy and strategy development; and capacity
building. A final evaluation report was completed in December.
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Exploratory studies in the field of drug demand reduction
Reviewing current practice in drug substitution treatment 
in the EU
In the framework of an EMCDDA study to identify practice in drug substitution treat-
ment in the EU, experts and key informants met in Rome in March to assess progress
and analyse results (contractors: Osservatorio Epidemiologico Regione Lazio, Italy,
and the National Addiction Centre, United Kingdom). The meeting explored: the
delivery of methadone and other substitution treatments; factors influencing the 
levels and quality of treatment provision; access to treatment; diversification of sub-
stitution drugs; use of primary care services; and drug substitution in prisons. The
final report prepared by the contractors was finalised in June. The report considered
issues such as: the extent of substitution treatment in Member States; legal controls
and service development; prescribing practice; types of opiate substitution; integra-
tion of services; monitoring and evaluation. It concluded that, over the previous five
years, there had been a major expansion in drug substitution treatment and a con-
siderable convergence in models of drug service delivery. A broader range of acces-
sible substitution treatment programmes has developed. However, given the extent
of the current services across Europe, there has been very limited research and eval-
uation of the treatment process that would provide good data not just to confirm the
benefits of treatment but also to indicate factors associated with good treatment.
Assistance to drug users in prisons
In December 1999, the EMCDDA began a study on demand-reduction interventions
in prisons. The objectives are: to obtain an overview of drug use in prisons and of
the state of the art in assistance to drug users; to describe the roles of in-prison ser-
vices and the involvement of local agencies in treatment; and to gauge the extent of
drug-free and substitution treatment, prevention and general health care in this set-
ting. The study, due for completion in August 2000, will specifically collect results
of evaluation studies and define evaluation criteria for demand- and harm-reduction
interventions in prisons in the EU (contractor: Oldenburg University, Germany).
Qualitative research in the field of drug demand reduction
In January 1999, the EMCDDA embarked on a study on qualitative research in the
field of drug demand reduction. The purpose of the study was: to inform policy-
makers and practitioners about recent demand-reduction research; to promote this
research; and to facilitate networking among researchers in the field. The project
complements the EMCDDA’s qualitative research study in the area of epidemiology
launched in 1996 to analyse drug-use patterns. The results of the study were pre-
sented at an EMCDDA seminar in Lisbon from 7 to 9 October (contractor: Nordic
Council for Alcohol and Drug Research/NAD, Finland).
The study and the seminar revealed that qualitative research in the field of demand
reduction could be categorised at three levels, all of which have been approached
to a differing degree:
• individual responses to drug demand-reduction activities (most commonly
found);
• evaluation of single demand-reduction projects (less commonly found and
few including the delivery of services); and
• studies of demand-reduction networks, systems, cooperation between services
(rarely found).
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The outcome of the study is an inventory which includes: an annotated biblio-
graphy; country profiles on the state of the art; recent and ongoing research and
researchers interested in qualitative research; and a synthesis of key research find-
ings. The inventory is published at the following website (http://www.qed.org.uk).
Roles, structures and cooperation 
in drug-demand reduction services
At the end of 1999, as a follow-up to the abovementioned study on qualitative
research, the EMCDDA embarked on a preliminary study to propose a research
design for a study on roles, structures and cooperation in drug-demand reduction
services in the health, social, educational and criminal justice sectors. The hypoth-
esis behind this study is that inconsistencies, incoherence and rigid structures may
be detrimental to effective drug demand-reduction strategies at national, regional
and local levels, whereas formal and informal cooperation structures may improve
the drug situation. Very little is known about the mechanisms of drug demand-
reduction policy planning and implementation at national, regional and local 
levels. The study intends to shed light on this area, demonstrate examples of good
practice, and improve information collection, analysis and dissemination (contrac-
tor: Rand Europe, the Netherlands).
Reports and output of projects, 1999
Demand reduction
• ‘Demand-reduction networking in Austria, Ireland, the Netherlands, Spain
and Sweden’
• ‘Reviewing current practice in drug substitution treatment in the European
Union’
• ‘Implementation of the guidelines for the evaluation of drug prevention’
• ‘Outreach work among drug users in Europe’
• ‘Demand-reduction activities in the field of synthetic drugs’
Major meetings organised by the EMCDDA, 1999
Demand reduction
Date Place Event
26 March EMCDDA EDDRA managers meeting
3 September EMCDDA Third steering committee meeting of the
EMCDDA/UNDCP/WHO project on costs and
effects of treatment of substance use disorders
7–9 October EMCDDA Meeting on qualitative research in drug
demand reduction
25–26 October EMCDDA EDDRA managers meeting
2–4 December Strasbourg EMCDDA/European Commission: Second
European Conference on the Evaluation of
Drug Prevention 
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Major meetings attended by the EMCDDA, 1999
Demand reduction
Date Place Event
17–18 January Helsinki Brainstorming meeting on qualitative research
in drug demand reduction, Nordic Council for
Alcohol and Drug Research (NAD)
16 February Madrid Conference ‘Jornadas sobre prevención de
drogodependencias en el ámbito laboral’,
Plan Nacional sobre Drogas, Spain
26–27 February Athens World Psychiatric Association Congress
12 March Luxembourg Meeting of the coordinators of the third
European Drug Prevention Week, European
Commission
15–17 March Vienna UNDCP working group on a draft action plan
on the Guiding principles of drug demand
reduction
29–31 March Tenerife Annual conference of Sociodrogalcol
21 April Bergen Meeting of the Nordic Ministerial Council’s
civil servants’ committee on narcotic drugs
9–12 May Sundsvall Private-sector conference on demand reduc-
tion in the workplace, International Labour
Organisation (ILO) and UNDCP
14–15 May Ferrara Seminar on the adaptation of the EMCDDA’s
‘Guidelines for evaluation of drug prevention’
in Italy, European Commission’s COST A-6
programme
15 May Rome Meeting of the International reference group,
Centro Italiano di Solidarietà, Italy
20–21 May Stockholm Final meeting of the Reitox project on net-
working in the field of demand reduction 
21–22 May Milan European Foundation of Drug Helplines
(FESAT) evaluation meeting
13–16 June Prague Phare summer school on synthetic drugs
24–25 June Halle Conference, European Cities on Drug Policy
11–13 July Helsinki Seminar on best practices in drug prevention
by law enforcement authorities
28–31 August Nuuk Annual Nordic drug prevention conference,
City of Nuuk
15–17 Hamburg New ways in European drug policy and 
September addiction research, University of Hamburg
23–24 Madrid Cooperation seminar between NIDA and 
September the Spanish Plan Nacional sobre Drogas on
the evaluation of preventive interventions in
view of drug dependency and HIV/AIDS
27–29 Bilbao Conference on safety and employability,
September the European Agency for Safety and Health 
at Work
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4–6 October Strasbourg Seminar on drug misusing offenders in prison
and after release, Pompidou Group
11–13 October Erfurt International seminar on alcohol prevention,
Thüringer Koordinierungsstelle für Sucht-
prävention
11–13 October Tampere European conference on the promotion of
mental health and social inclusion, Finnish
Presidency
14–16 October Ljubljana Phare project on technical assistance to drug
demand reduction, regional seminar
April– Belgium National EDDRA and evaluation 
December Germany training seminars 
Greece
Spain
Netherlands
Portugal
Finland
Articles published, 1999
Demand reduction
Burkhart, G., ‘Comentario sobre reducción de la demanda en el medio 
laboral’ in Prevenlabor, No 2, June 1999
Burkhart, G., ‘Use of telematics from the viewpoint of an international organi-
sation: the EMCDDA’ in Peltoniemi, T., Tammi, T. (eds.), Guidelines for tele-
matic drug and alcohol prevention (Helsinki: A-Clinic Foundation/Prevent
Euro, 1999)
Burkhart, G., ‘Evaluación de los programas de prevención, una necesidad
posible’ (http://w3.arrakis.es/iea/boletin/opinion22.htm), June 1999
Kinnunen, A., and Nilson, M., ‘Recent trends in drug treatment in Europe’ in
European Addiction Research, Vol. 5, No 3, 1999
Nilson, M., ‘Drug use among vulnerable groups of young people: comments’
in Education, Prevention and Policy, Vol. 6, No 2, 1999, pp. 203–204
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Chapter 3
Reitox coordination
The main work of the Reitox coordination department in 1999
corresponded to priority objectives 2 and 5 of the 1998–2000 work
programme. The implementation during the year of the paper on ‘The role
and financing of the national focal points’, adopted by the EMCDDA
Management Board in 1998, significantly improved the morale and
capacity of the national centres, several of which had previously suffered
on account of insufficient resources. This, in turn, strengthened
cooperation between the network and the EMCDDA, as recommended in
the European Parliament’s ‘Schaffner Report’ in 1998 (14).
In 1999, the network worked towards two major long-term objectives:
taking forward a network of national focal points which operates to the
highest professional standards; and establishing an evaluation and
quality-control package for the transmission of data and all other
deliverables. A new Reitox staff member was recruited in 1999 to
concentrate in 2000 on enhancing quality control and output and as well
as communication with the national focal points and other EMCDDA
departments.
(14) Document A4-0294/98. Report on the Annual report on the state of the drugs problem in the European
Union 1997 of the European Monitoring Centre for Drugs and Drug Addiction (C4-0552/97). Committee
on Civil Liberties and Internal Affairs, Rapporteur, Anne-Marie Schaffner. 
1998–2000 work programme
Reitox, activities in 1999
Priority objective 2
Consolidating and enhancing the Reitox network in accordance with the deci-
sions taken by the EMCDDA Management Board
Core tasks
Support projects
Priority objective 5
Developing structured cooperation with the EMCDDA’s international partners
and ensuring synergies and complementarity with EU programmes and activi-
ties, avoiding any duplication of work
Further involvement of the CEECs in the activities
of the EMCDDA and Reitox
While the majority of the department’s activities focused on the above objec-
tives, it also played a fundamental role in the execution of priority objectives
1, 3, 4 and 6.
Other activities
Networking, discussion and dissemination
Core tasks
In 1999, the Reitox national focal points undertook four core tasks (15):
• the updating of national reports describing the drug situation in their country
in 1998;
• active participation in, and contribution to, the electronic information system,
Exchange on drug demand-reduction action (EDDRA) (see Chapter 2);
• participation, at national level, in the early-warning system on new synthetic
drugs foreseen by the 1997 joint action on new synthetic drugs;
• active participation in the progressive implementation of five harmonised 
epidemiological key indicators.
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(15) In previous years, the core tasks have included the compilation of an ‘information map’, an instrument
devised by the EMCDDA to record in detail the sources, availability, quality and flow of information in
the different EU Member States. Documentation normally collected via the information map exercise
was not gathered in 1999 due to the fact that guidelines for updating the information map were being
revised in the context of a new national reporting process. In 2000, the NFPs will once again be
required to update the country information maps on the basis of these new guidelines. 
National reports
The focal points drew up their national reports for 1998 and submitted them to the
EMCDDA by the end of February. These provided the Centre with vital data, among
others, for its Annual report on the state of the drugs problem in the European Union
1999.
The national reports included three key themes as selected at a special Reitox ses-
sion in November 1998. The themes were: trends and responses to old and new
synthetic drugs; prevention and good practice in the European Drug Prevention
Week; and ‘cannabis revisited’, prevention, treatment and medical and policy
developments.
Some delays in the delivery of the national reports occurred, partly due to delays at
the EMCDDA in finalising a set of guidelines for compiling the reports and partly
due to the fact that the NFPs did not hold the complete set of 1998 data as early as
February. As a result, the Management Board adopted a new reporting process in
October harmonising national and EMCDDA reporting calendars. This took into
account, on the one hand, the timespan required at national level for obtaining a
complete set of data, and, on the other hand, the time required by the EMCDDA to
analyse these data and to compile, edit and publish the final Annual report.
In preparation for the 2000 Annual report, the NFPs submitted their 1999 national
reports to the EMCDDA in the period August–October (epidemiological data) and
October–December (data on demand-reduction activities, new trends, policy and
legislation changes, key-issues, etc.).
Exchange on drug demand-reduction action (EDDRA)
This information system on drug demand-reduction activities is fed by ‘EDDRA
managers’ at the 15 national focal points who input into the system data on
demand-reduction projects in their country which fulfil particular operational and
scientific criteria. As a result of their efforts in 1999, EDDRA carried information on
over 150 projects by the end of the year (see Chapter 2).
Joint action on new synthetic drugs
On 24 June, the EMCDDA released an urgent information briefing through the Reitox
network concerning the effects of the new synthetic drug 4-MTA (see Chapter 4),
a substance brought to its attention via the early-warning and risk-assessment mech-
anisms provided by the joint action on new synthetic drugs. This briefing urged the
national focal points to disseminate accurate information on the risks of the drug to
their national channels (including health services and the media) following mis-
leading reports in the press. The substance was finally placed under control by a
Council decision on 13 September.
Harmonised epidemiological indicators
The national focal points are required to actively promote the progressive imple-
mentation within their Member State of the five key harmonised epidemiological
indicators under development by the Centre since 1998 (see Chapter 1). The NFPs’
first task was to draw up detailed work plans which included the establishment of a
national group for each indicator. First priority was given to four indicators: national
prevalence estimates of problem drug use; demand for treatment by drug users; drug
use in the general population (population surveys); and drug-related deaths. Work
plans related to these indicators were completed by the NFPs in mid-December. The
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NFPs were also required to submit to the EMCDDA, by the end of 1999, progress
reports regarding the implementation at national level of these four indicators. 
The work plan on the infectious diseases among injecting drug users indicator is
expected to be delivered by the NFPs in the first half of 2000.
Support projects
The objectives of the Reitox support projects (formerly ‘Reitox specific projects’) are
threefold: to support the work of the Reitox network and its core tasks (directly or
indirectly); to introduce further initiatives into the work of the network by conduct-
ing more in-depth studies related to some core tasks; and to decentralise responsi-
bility for the management of the core tasks to appropriate national focal points.
The number of these support projects undertaken per year depends on: EMCDDA
Management Board priorities; discussions with the national focal points; the needs
of individual departments to conduct more in-depth studies related to Reitox core
tasks; financial resources; and the work of the Centre as a whole. The outcome of
these support projects constitutes the groundwork for further and more in-depth
implementation of the Reitox core tasks by the network.
With a view to complementing, assisting and deepening work related to some of the
core tasks, support projects were undertaken in 1999 by NFPs specialised in those
fields. They included:
• implementing the treatment-demand indicator;
• improving the comparability of indicators related to drug-related deaths;
• supporting the development of national prevalence estimates in order to
improve their comparability;
• improving evaluation skills, using the EMCDDA’s guidelines for the evaluation
of prevention activities and its information system on demand-reduction activ-
ities (EDDRA) (see Chapter 2);
• consolidating EDDRA;
• developing networks in the field of demand reduction; and
• enhancing EMCDDA-Reitox collaboration in the evaluation exercise of the
joint action on new synthetic drugs and its implementation by the NFPs at
national level (see Chapter 4).
Further involvement of the CEECs in the activities
of the EMCDDA and Reitox
See cluster groups below.
Networking, discussion and dissemination
Common EMCDDA-Reitox electronic network
The common EMCDDA-Reitox electronic network, set up with funding from the
European Commission’s interchange of data between administrations (IDA) I pro-
gramme, was increasingly used in 1999 by the Reitox community (EMCDDA and
national focal points) for disseminating and exchanging information and promoting
understanding and transparency within the network. These actions were undertaken
using electronic services such as the private Reitox community website which,
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among others, allows: e-mail communication; transfer of minutes, documents,
papers and data; agenda consulting; and participation in discussion groups.
During the year, the Reitox community prepared for the further development of the
common electronic network, including the extension of services and the integration
of new partners. Concrete steps in 2000 will be subject to the availability of funds
under the IDA II project. 
In 1999, the NFPs were requested to link their individual websites to the Centre’s
public website in an attempt to increase homogeneity and user-friendliness. 
Drug demand-reduction networking
The need to consolidate information networks in the field of drug demand reduc-
tion has arisen from difficulties experienced by the NFPs in accessing projects while
preparing national reports and input to the EDDRA database. The EMCDDA
embarked on a project to overcome these obstacles in September 1998, in cooper-
ation with the national focal points of Spain, Ireland, the Netherlands, Austria and
Sweden (see Chapter 2). A final seminar on the project was hosted by the Swedish
national focal point (coordinator) in May and a report presented at the Reitox meet-
ing in November. By creating demand-reduction networks, the NFPs will be able to
disseminate information to professionals for support in daily practice. At the same
time, relevant information may be collected by the EMCDDA and the NFPs and
shared with partners, thereby contributing to the future development of the
European dimension of demand-reduction.
Cluster groups
In addition to the three meetings of the national focal points held in Lisbon in 1999
(into which topic-focused workshops were programmed to ensure full coverage of
important issues), the EMCDDA also set up Reitox ‘cluster groups’ (topic-focused
groups comprising selected focal points). Cluster group meetings were attended by
the Reitox coordination department and NFPs with a special interest in a particular
subject. Larger single-issue meetings may also be instituted in the future, hosted by
individual NFPs.
National networks: identity and diversity
A cluster group comprising the EMCDDA and the national focal points of Belgium,
Spain and the United Kingdom was hosted by the Spanish focal point in Madrid in
February. The aim of the meeting was to exchange views on how to respond to: 
different cultural identities; autonomous communities; local diversity in language;
and national and regional parliaments and their descendant structures. The partici-
pants agreed that clear definitions and criteria were required to clarify expectations
at local level. Feedback and dissemination were seen as an essential way of moti-
vating local and national networks.
Central and eastern Europe: exploring the future
A Reitox cluster group met in Munich in April to discuss common interests and col-
laboration with the central and east European countries (CEECs) (16). The meeting
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(16) The 13 CEECs are: Albania, Bosnia and Herzegovina, Bulgaria, Czech Republic, Estonia, Former
Yugoslav Republic of Macedonia (FYROM), Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and
Slovenia. Ten of these (all except Albania, Bosnia and Herzegovina and FYROM) are candidate coun-
tries for accession to the European Union. Other candidate countries are Cyprus, Malta and Turkey.
was attended by the national focal points of Germany, France, the Netherlands and
Sweden and was hosted by the German focal point. These four NFPs were active
participants in the Phare-DIS project (see Chapter 8) and assisted the CEECs in the
drafting of their 1997 national reports. They were also the authors of three sub-
regional reports now available at the following website (http://www.fad.phare.org).
The group considered that decision-making mechanisms and processes would need
to be explained and clarified to potential Reitox members from this region prior to
any assimilation into the network. In this respect, they supported the feasibility of
future clustering between existing Reitox, and developing CEEC, focal points and/or
local contact persons. The participants at the meeting felt that progress should be
made as soon as possible in developing networks for the collection and dissemina-
tion of drug-related data in the CEECs and across Europe. Once a Reitox-style net-
work has been established in the CEECs, dissemination of data and feedback on
national reports would be of particular importance to national centres in the region.
Dissemination of the EMCDDA’s publications and products
In 1999, the national focal points continued to disseminate EMCDDA publications
and products on request. Although such dissemination is not a Reitox core task, it
was considered by the majority of NFPs in 1999 to be important for providing added
value to their own national networks and partners.
Reports and output of projects, 1999
Reitox
• National focal point national reports for 1998
• National focal point reports on recent developments and trends, 1999
• National focal point reports on the implementation of the joint action on new
synthetic drugs at national level, 1999
• National focal point reports on the implementation of the information system
on demand-reduction activities, 1999
• National focal point work plans regarding the implementation of the 
epidemiological key indicators at national level, 1999
Major meetings organised by the EMCDDA, 1999
Reitox
Date Place Event
4 February Madrid EMCDDA-Reitox cluster group meeting on
national networks: identity and diversity
17 February EMCDDA EMCDDA-Reitox meeting on networking in
the field of demand reduction
18–19 February EMCDDA 16th meeting of the heads of the Reitox
national focal points
26 March EMCDDA EMCDDA-Reitox ‘EDDRA managers’ meet-
ing
22–23 April Stockholm EMCDDA-Reitox meeting on networking in
the field of demand reduction
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29 April Munich EMCDDA-Reitox cluster group meeting on
central and eastern Europe 
21–22 May Stockholm EMCDDA-Reitox meeting on networking in
the field of demand reduction
21–22 June EMCDDA 17th meeting of the heads of the Reitox
national focal points
21–22 October Lisbon Pilot meeting on drug action planning evalu-
ation framework
16–17 November EMCDDA 18th meeting of the heads of the Reitox
national focal points
Major meetings attended by the EMCDDA, 1999
Reitox
Date Place Event
20 January Vienna UNDCP expert seminar
20 January Vienna Visit to the Austrian national focal point
20–21 January Brussels IDA project steering committee, Directorate-
General for Enterprise
2 February Brussels Visit to the Belgian national focal point
3 February London Visit to the UK national focal point
4 February Madrid Visit to the Spanish national focal point
15 March Brussels IDA project: brainstorming on Reitox-IDA
project extension, EC focal point and Belgian
national focal point
16 March Utrecht Visit to the Dutch national focal point
17 March Luxembourg Visit to the Luxembourg national focal point
15–16 April Rome Visit to the Italian national focal point
26 April Utrecht Visit to the Dutch national focal point
27 April Paris Visit to the French national focal point
28 April Munich Visit to the German national focal point
27 May Brussels Reitox-IDA II project, Directorate-General
for Enterprise 
10–11 June London Programme committee for the 11th Interna-
tional Conference on Drug-related Harm
12 July Dublin Visit to the Irish national focal point
13 July London Feasibility meeting on drug action planning
evaluation framework, Centre for Research
on Drugs and Health Behaviour
14 July London International Conference on Heroin and
Public Health, Release 
22 July Rome Meeting to discuss the structure of new
Italian national focal point
4 August Lisbon Visit to Portuguese national focal point
10 September Brussels Reitox-IDA II project, Directorate-General
for Enterprise
21 September Vienna Meeting with head of the Austrian national
focal point
11 October Athens Visit to the Greek national focal point
45
Chapter 3: Reitox coordination  
Articles written or papers delivered, 1999
Reitox
The following papers were presented at events during the year:
‘Studying local and national drug markets’, UNDCP expert seminar, 20
January, Vienna
‘Heroin, where next?’, Release International Conference on Heroin and Public
Health, 14 July, London
‘Outreach and qualitative research’, expert seminar on qualitative research in
demand reduction in Europe, 7 October, EMCDDA
‘Mobilising live networks’, 11th annual meeting of the European Association 
of Libraries and Information Services on Alcohol and other Drugs (ELISAD),
4 November, EMCDDA
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Chapter 4
National and Community
strategies
In 1999, the EMCDDA embarked on the second priority area listed in the
annex to its founding regulation, namely ‘national and Community
strategies and policies’. During the year, in the field of national
strategies, the Centre focused on drug-related legislation in the EU
Member States, and the cross-country comparison thereof, as well as on
policy developments in preparation for the Annual report on the state of
the drugs problem in the European Union 1999. 
Complementing the above, in the field of Community strategies, the
Centre continued to focus on the legal vacuum regarding synthetic drugs
in the EU. This was achieved under the terms of the joint action
concerning the information exchange, risk assessment and control of
new synthetic drugs, adopted by the Council of the European Union in
June 1997, and took the form of specific case studies on new substances
appearing on the European market. The latter offered the Centre the
opportunity to combine its information-collection and scientific-
evaluation expertise to influence decision-making on drugs in the EU.
The major achievements carried out in this area relate to priority
objectives 1, 2, 5 and 6 of the 1998–2000 work programme. Work carried
out in 1999 was undertaken by the section of the EMCDDA attached to
the director’s office responsible for new synthetic drugs, international
cooperation and legal information 
(for international cooperation see Chapter 8).
1998–2000 work programme
National and Community strategies, activities in 1999
Priority objective 1
Consolidating and improving the Centre’s epidemiological and demand-
reduction information systems on the basis of agreed sets of core data
(b) New trends: setting up and developing a mechanism for the information
exchange, risk assessment and control of new synthetic drugs
Mechanism for the implementation of the joint action
on new synthetic drugs
Priority objective 2
Consolidating and enhancing the Reitox network in accordance with the deci-
sions taken by the EMCDDA Management Board          
Joint action on new synthetic drugs and the Reitox network
Priority objective 5
Developing structured cooperation with the EMCDDA’s international partners
and ensuring synergies and complementarity with EU programmes and activi-
ties, avoiding any duplication of work
Cooperation in the field of new synthetic drugs and legal information
Priority objective 6
Developing tools and methodologies for comparing interventions, legislation,
strategies and policies in the EU (including cost-effectiveness evaluation)
Collecting and analysing drug-related legal information
Mechanism for the implementation of the joint action
on new synthetic drugs
Information exchange
The adoption of the joint action on new synthetic drugs in 1997 provided the
EMCDDA and Europol with a clear mandate to coordinate the collection and
exchange of information on any new synthetic substance appearing on the
European market. In 1999, the mechanisms and processes previously set up to
implement the joint action were further developed and consolidated. During the
year, an information collection and exchange system was established via the respec-
tive networks of the EMCDDA and Europol: the Reitox national focal points and the
Europol national units.
Early in January 1999, the EMCDDA and Europol prepared a joint progress report,
which provided preliminary information on the new synthetic drug 4-MTA
(4-methylthioamphetamine) which had been collected and exchanged under 
Article 3 of the joint action (information exchange). Europol had covered the pro-
duction and trafficking aspects of the drug while the EMCDDA had looked at use
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and the possible health and social risks of the substance. The report had been trig-
gered by large seizures of the drug in the second half of 1998 and by a number of
deaths allegedly linked to the substance.
On 22 January, the joint report was submitted to the chairman of the Horizontal
Drugs Group (HDG) of the Council of the EU, the Council Secretariat and the
European Commission for consideration. In February, the German Presidency of the
EU formally referred the case of 4-MTA to the EMCDDA and Europol for risk assess-
ment under Article 4 of the agreement.
Risk assessment
The joint action assigns the EMCDDA and Europol a key role in the risk assessment
of new synthetic drugs under the auspices of the EMCDDA Scientific Committee. In
1999, a working methodology and ‘Guidelines for the risk assessment of new syn-
thetic drugs’, adopted in Autumn 1998, were further developed (and published in
July, see Chapter 5).
The Scientific Committee’s steering group — established in November 1997 to pre-
pare the risk-assessment procedure — met five times in 1999 (see Chapter 7). The
‘Guidelines for the risk assessment of new synthetic drugs’ were examined and fur-
ther developed at these meetings and progress was made on measures to improve
future risk-assessment procedures. With regard to the latter, a technical evaluation
meeting, composed of scientific experts, met on 29 November 1999 to assist the
EMCDDA in compiling a shortlist of laboratories for toxicity testing within the
European Union. This move stemmed from proposals from the risk-assessment
meeting on MBDB (N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine) of 9 and 10
November 1998 that an inventory of suitable laboratories with recognised expertise
in toxicity testing be drawn up for the purpose of providing standard toxicity data
when a new synthetic drug is notified for risk assessment.
On 19 April, a high-level expert group on the pharmacotoxicology of 4-MTA met at
the EMCDDA. Discussions were based on the scientific literature on the substance
and on its current incidences. A literature review on 4-MTA (compiled externally)
and comments thereon, were submitted to the Scientific Committee on 17 and 18
May and to a special risk-assessment meeting on 18 and 19 May (see below). These
were included in the technical annexes to the final risk-assessment report on 4-MTA
in accordance with the ‘Guidelines for the risk assessment of new synthetic drugs’.
From 18 to 19 May, a formal risk assessment of the drug was carried out by the
EMCDDA Scientific Committee and experts in Lisbon (see Chapter 7). This special
risk-assessment session examined the health and social risks of the substance and
the possible consequences of prohibition. The result was the formal adoption on 
19 May of the ‘Report on the risk assessment of 4-MTA in the framework of the joint
action on new synthetic drugs’, released as an EMCDDA publication in October
(see Chapter 5). The report concluded that 4-MTA should be placed under control
in the Member States largely due to the high risks of overdose associated with it.
Control
The above ‘Report on the risk assessment of 4-MTA’ was forwarded to the German
Presidency of the HDG of the Council, to the Secretary-General of the Council and
to the European Commission on 24 May in accordance with Article 5 of the joint
action (procedures for bringing specific new synthetic drugs under control).
Following discussions at the meeting of the HDG on 18 June, the Commission sub-
mitted a proposal to the Council on 7 July calling for the drug to be subject to 
control measures.
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Following the Commission’s proposal, the EU Council of Justice and Home Affairs
adopted, on 13 September, a decision defining 4-MTA as a substance ‘to be made
subject to control measures and criminal penalties’ in the EU Member States (see
footnote 4). Under this decision, and in accordance with their national laws,
Member States were given a three-month time limit to introduce the necessary 
steps to submit 4-MTA to control measures and criminal penalties as provided under
the 1971 UN Convention on Psychotropic Substances.
The speed and effectiveness of the mechanisms provided under the two-year-old
joint action were confirmed in 1999 during the risk assessment of 4-MTA which was
concluded within a matter of six months and involved all three stages of the joint
action (information exchange, risk assessment and control).
This was the second such exercise undertaken to date by the EMCDDA, the first
involving MBDB. (A ‘Report on the risk assessment of MBDB in the framework of
the joint action on new synthetic drugs’ was released as an EMCDDA publication in
June 1999. See Chapter 5.) Since no consensus on MBDB was reached by the HDG
of the Council of the EU in December 1998, the group decided in April 1999 to
introduce a six-month monitoring of the market for MBDB and its hazardous effects.
On 17 November 1999, an EMCDDA-Europol progress report on the monitoring of
MBDB was presented to the HDG. The group subsequently decided not to ask
Member States to submit the substance to common control measures at EU level
and to inform Coreper on this advice.
Joint action on new synthetic drugs and the Reitox network
In 1999, the national focal points of the Reitox network promoted mechanisms at
national level for information collection and exchange and the detection of new
substances within the EU. The EMCDDA requested information from Reitox on 
4-MTA, GHB (Gamma-hydroxybutyrate) and Ketamine as well as updated informa-
tion on MBDB. It also launched a technical evaluation study of the mechanisms 
set up to implement the joint action on new synthetic drugs (contractor: Reitox
national focal point, Belgium). On 24 June, the EMCDDA released an urgent infor-
mation briefing through the Reitox network on the effects of the new synthetic drug
4-MTA (see Chapter 3).
Cooperation in the field of new synthetic drugs and legal
information
Cooperation in the field of new synthetic drugs
Practical cooperation between the EMCDDA, Europol, the European Commission’s
Drugs Coordination Unit and the European Agency for the Evaluation of Medicinal
Products (EMEA) was consolidated in 1999. The common instruments and inter-
faces between the EMCDDA and Europol were also developed in the framework of
the joint action.
Cooperation in the field of legal information
During 1999, the EMCDDA and the United Nations International Drug Control
Programme (UNDCP), in applying their memorandum of understanding signed in
March 1998, closely collaborated to improve the collection and exchange of legal
data and texts received by EU Member States.
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Collecting and analysing drug-related legal information
Legal information system on drugs
In 1999, the EMCDDA launched a procedure to set up a legal information system
on drugs based on close cooperation with the EU Member States and with the
UNDCP.
In June, the EMCDDA Management Board approved the creation of the legal infor-
mation system. This system is designed to enable the EMCDDA, in accordance with
its mandate, to provide up-to-date and comparable information on national drug
laws, regulations and their application in the EU Member States in the context of
specific issues.
The first phase of the project will be to collect and store the texts of key drug laws
while, the second phase will focus on analysis and comparison. The system will
offer the possibility for on-line consultation of the latest texts of drug laws and will
present comparable data to allow analysis of legal and judicial approaches to the
drug phenomenon in the EU.
The decision to set up such as system reflects the needs of national and European
decision-makers and professionals to dispose of ‘objective, reliable and comparable
information’ in the area of national and Community strategies and policies (priority
area 2 of the EMCDDA’s founding regulation).
The system is composed of three elements:
• a database;
• a network of legal contact persons;
• analysis of the application of the law.
Database
The legal database is designed to contain the legal texts on drugs in force in the EU
Member States as well as general information on drug laws. The database aims to
collect, store and classify the countries’ basic drugs legislation in an electronic
inventory allowing easy access and cross-country comparison. Possibilities for rapid
retrieval of specific subjects or of specific articles of a law will be incorporated into
the navigational structure of the system. The main objective of this database is to
facilitate the monitoring and analysis of legal responses to the drug phenomenon.
Access will be offered via the Internet.
Network of legal contact persons
To ensure the regular updating of data contained in the legal database, and to
exchange information on new strategies and policy interventions, the EMCDDA
Management Board was requested to nominate in late 1999 a ‘legal contact person’
or representative in each EU Member State. Collaboration between the EMCDDA
and these national legal specialists will allow the Centre to keep up to date with
drug legislation and drug strategies in the EU.
Analysis of the application of the law
The EMCDDA is examining ways in which drug laws are enforced in practice and
underlines the importance of comparative cross-country analysis of this application.
In December, a study on the ‘prosecution of drug misusers’ was launched by the
Centre. The objective of this study is to look at the link between the law and legal
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system of a country and action taken by the police and judicial authorities towards
drug offenders. This study will explore the feasibility of creating a group of indica-
tors in the penal policy domain through available data or topics collected by a
majority of Member States. Results are due in 2000.
CD-ROM: European Union legal texts on drugs
European Union legal texts on drugs, the EMCDDA’s first CD-ROM, was published
at the end of 1999 (see Chapter 5). The CD-ROM contains over 200 key legal texts
issued by the European Union institutions in relation to the drugs phenomenon,
including regulations, directives, decisions, joint actions, as well as conclusions of
the European Council meetings and action plans on drug issues.
Produced in response to the growing interest in drug legislation and policies in
Europe, the CD-ROM provides the European Union Member States, their EU part-
ners, other institutions, practitioners in the drugs field and the general public with a
practical overview of Community strategies and policies on drugs and related legis-
lation passed since the late 1980s. Presented in an accessible and user-friendly for-
mat, this specialised product provides a wealth of useful information for all those
interested in the drug situation in the European Union.
Study on public expenditure
In response to frequent requests, and in order to meet the requirements indicated in
priority area 2 of the Centre’s founding regulation, the EMCDDA launched in
December 1999 a comparative study to analyse public expenditure on drugs in the
EU countries (contractor: Pierre Kopp, France).
The purpose of this study is to establish the costs borne by each Member State in
implementing national drugs policy. It will distinguish between direct and indirect
expenditure and encompass the different areas of national expenditure (prevention,
treatment, law enforcement). Furthermore, the study will compare the total ‘drug
budget’ amounts with other standard macroeconomic aggregates (e.g. ‘drug 
budget’/GNP and ‘drug budget’/total public expenditure).
The results will be compiled in a report offering a comparative overview of public
expenditure in the EU Member States relating to drugs. The EMCDDA will consider
the publication of this report in 2001.
Reports and output of projects, 1999
National and Community strategies
New synthetic drugs
• ‘EMCDDA-Europol progress report on 4-MTA’ in accordance with Article 3
of the joint action on new synthetic drugs of 16 June 1997
• ‘EMCDDA-Europol progress report on the monitoring of MBDB’
• Mallaret, M., ‘Review of the pharmacotoxicological data on 4-MTA’
• ‘Report on the risk assessment of 4-MTA in the framework of the joint action
on new synthetic drugs’
• ‘Evaluation of the mechanisms set up for the implementation of the joint
action on new synthetic drugs’, Reitox national focal point, Belgium
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Major meetings organised by the EMCDDA, 1999
National and Community strategies
Date Place Event
New synthetic drugs
19 April EMCDDA High-level expert and steering group meeting
on new synthetic drugs (4-MTA)
17 May EMCDDA Steering group meeting on new synthetic
drugs
18–19 May EMCDDA Special risk-assessment meeting (extended
EMCDDA Scientific Committee)
19 May EMCDDA Steering group meeting on new synthetic
drugs
29 November EMCDDA Technical evaluation meeting on toxicity-
testing laboratories
30 November EMCDDA Steering group and expert meeting on new
synthetic drugs
7 December EMCDDA Steering group meeting on new synthetic
drugs
Major meetings attended by the EMCDDA, 1999
National and Community strategies
Date Place Event
New synthetic drugs
January– Brussels Meetings of the Horizontal Drugs Group 
December under the German and Finnish Presidencies
(see Chapter 8)
11 January The Hague EMCDDA-Europol meeting on 4-MTA in
accordance with Article 3 of the joint action
on new synthetic drugs
14 June Brussels Information and discussion meeting on anti-
fraud and research and technology activities,
Directorate-General for Enterprise
25–26 October Biarritz First European meeting on drug abuse and
dependence
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Legal information
11 February London ‘Meeting the challenge: drug facts and legal
responses’, Release 
19 February Vienna Meeting with the UNDCP legal section on an
exchange of legal data on drugs
9 March Madrid Meeting with member of the EMCDDA
Management Board, Spain
17–19 March Vienna Meeting with the UNDCP legal section on an
exchange of legal data on drugs
13 April London Meeting with members of the EMCDDA
Management Board, the Netherlands and the
United Kingdom
16 April Lisbon Meeting with member of the EMCDDA
Management Board, Portugal
4 May Paris Meeting with member of the EMCDDA
Management Board, France
5 May Brussels Meeting with member of the EMCDDA
Management Board, Belgium
6 May Dublin Meeting with member of the EMCDDA
Management Board, Ireland
12 May Copenhagen Meeting with member of the EMCDDA
Management Board, Denmark
17 May Stockholm Meeting with member of the EMCDDA
Management Board, Sweden
18 May Helsinki Meeting with member of the EMCDDA
Management Board, Finland
21 May Bonn Meeting with member of the EMCDDA
Management Board, Germany
6–8 September Rome Seminar on risk analysis of transnational 
traffic, Italian Ministry of the Interior
6–10 December Vienna Expert working group on improving inter-
sectoral impact in drug-abuse offender case
work, UNDCP
Articles written or papers delivered, 1999
National and Community strategies
Legal information
Ballotta, D., ‘Established scenes and developing trends in drug use: the need
for a new collective response’, in Interpol and technology in partnership: fight-
ing drugs, National Criminal Intelligence Service (NCIS), 1999, 
pp. 34–36
Ballotta, D., ‘Offence, a punishment for drug consumption in the EU’, paper
presented to the UK Home Office, October 1999
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Chapter 5
Information strategies and
communication resources
The information strategies and communication resources department
encompasses publications, media relations, web dissemination,
documentation and information technology (IT). In 1999, the EMCDDA’s
work in these fields corresponded primarily to priority objective 4 of the
1998–2000 work programme.
Major results included the publication of the fourth Annual report on the
state of the drugs problem in the European Union and its launch to the
media and general public in November. This was followed by the launch
of a completely redesigned and restructured EMCDDA website at the
‘Online Information 99’ exhibition in London in early December. 
Other key achievements in 1999 included three publications on the results
of work undertaken in relation to the 1997 joint action on new synthetic
drugs; the inauguration of the EMCDDA’s Intranet; and consolidation of the
EMCDDA’s information-technology environment.
1998–2000 work programme
Information strategies and communication resources, activities in 1999
Priority objective 4
Improving the quality of the Annual report on the state of the drugs problem in
the European Union, the visibility of the work of the EMCDDA and the Reitox
network and the dissemination of the information collected and produced by
the EMCDDA
EMCDDA publications
Media relations
EMCDDA public website
EMCDDA Intranet
Documentation
Information technology 
EMCDDA publications
Production of the Annual report on the state of the drugs problem
in the European Union 1999
The Annual report on the state of the drugs problem in the European Union 1999
was launched by the EMCDDA on 22 November at a press conference at the Presse-
und Informationsamt der Bundesregierung in Berlin. The report is available in all 11
official EU languages. Targeted primarily at policy-makers, the 1999 Annual report
assembles new data and information from 1998 while updating findings from pre-
vious years. The topics covered in the volume include: developments in drug use,
problems and responses; prevalence, patterns and consequences of drug use; and
established responses to drug misuse in the EU. At the time of the launch, all 11 lan-
guage versions of the Annual report were downloadable from the EMCDDA’s web-
site (http://www.emcdda.org/publications/publications_annrep_99.shtml).
At the same time, the Centre published a 96-page Extended annual report in English
only which includes a selective glossary, references and sources of 
information as well as a list of recent EMCDDA publications. The Extended annual
report was also downloadable as were files of the overall trends in all 11 EU lan-
guages.
Production of other EMCDDA publications
In addition to the Annual report, the EMCDDA produces: an annual General report
of activities; a bimonthly newsletter, DrugNet Europe; and three specialised series
(the Scientific Monograph series; the Insights series; and the Manuals series). The
Centre also produces individual titles on an ad hoc basis (see table below). In late
1999, the EMCDDA produced its first CD-ROM, European Union legal texts on
drugs (see Chapter 4).
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Cooperation with the Office for Official Publications of the
European Communities (EUR-OP)
In 1999, the EMCDDA strengthened its relations with the Office for Official
Publications of the European Communities and the Centre’s publications staff paid
regular working visits to EUR-OP’s headquarters in Luxembourg. EUR-OP is now
responsible for the design, production and distribution of all EMCDDA publications
except for DrugNet Europe which is still produced and distributed locally. To facil-
itate communication between the two organisations and to increase the speed 
with which the EMCDDA responds to requests for its publications, the Centre was
granted access to EUR-OP’s on-line stock control and distribution system, Gescom,
in September.
Among issues discussed by the EMCDDA and EUR-OP in the second half of the year
was the drawing up of a specific contract for the EMCDDA’s publications and the
development of an EMCDDA ‘graphic chart’ to harmonise and streamline the
agency’s visual identity. This project will be pursued in 2000 if funds permit.
Participation in the European Publishers’ Forum
In 1999, the EMCDDA participated in the two meetings of the European Publishers’
Forum on 30 April in Brussels and on 14 October at the Frankfurt Book Fair (see
below). Among the issues discussed at the Brussels meeting were: the current status
of EU publishing; the dichotomy between commercial publishing and public-
information publishing; and the merits of priced versus free publications. The
Frankfurt meeting took the form of a question-and-answer session on various
aspects of publishing in Europe.
The forum, set up in 1996, is a joint initiative of the Federation of European
Publishers, the European Commission’s Directorate-General for the Information
Society and EUR-OP. The forum’s primary aims are: to promote the wider distribu-
tion of information produced within the EU institutions, both among these institu-
tions and to the broader public; to promote the wider distribution of issues of con-
cern to European citizens and of information about Europe to a broad audience; and
to promote contacts among European institutions and European publishers.
As a result of its participation at these events, the Centre has already received
requests from commercial publishers for the rights to republish some of its material
for the commercial market.
Participation in international exhibitions and fairs
Frankfurt Book Fair
From 13 to 15 October, the EMCDDA attended the Frankfurt Book Fair, the largest
international trade fair for the publishing world. The Centre participated at the EUR-
OP stand where it displayed its latest publications. The Centre’s work generated
much interest from other publishers attending the fair.
‘Online Information 99’
From 7 to 9 December, the EMCDDA attended ‘Online Information 99’ — an 
annual international conference and exhibition for electronic information profes-
sionals held in London — where it launched its new public website on 7 December
(see below). The Centre was among several EU services exhibiting both on-line and
57
Chapter 5: Information strategies and communication resources
paper products at the European Union stand. The EMCDDA distributed a news
release in the conference press packs (which carried the Centre’s logo) publicising
the aims and objectives of its on-line activities. The EMCDDA work station at the
stand received many visitors including: representatives of drug-related organisa-
tions; pharmacists; pharmacologists; academics; librarians; the media and educa-
tional professionals. 
EMCDDA publications, 1999
Title Languages
Annual report on the state of the drugs problem All 11 EU languages
in the European Union 1999
Extended annual report on the state of English
the drugs problem in the European Union 1999
General report of activities 1998 English, French, German
DrugNet Europe, issues 15–20 English, French, 
German, Portuguese
Outreach work among drug users in Europe: English
concepts, practice and terminology, 
Insights series No 2
Euro-Ibero American seminar: English, Portuguese, 
cooperation on drugs and drug addiction policies, Spanish
conference proceedings
Guidelines for the risk assessment English
of new synthetic drugs
Report on the risk assessment of MBDB English
in the framework of the joint action 
on new synthetic drugs
Report on the risk assessment of 4-MTA English
in the framework of the joint action 
on new synthetic drugs
European Union legal texts on drugs, CD-ROM English
Further details on all EMCDDA publications and details of how to order are available
on the EMCDDA website (http://www.emcdda.org/publications/publications.shtml).
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Media relations
In 1999, the EMCDDA took steps to consolidate and enhance its relations with the
media, to record the results of these contacts, and to analyse how to improve com-
munication with journalists via the provision of media-friendly information.
Contacts with the media
Throughout 1999, the EMCDDA received a constant stream of enquiries into all
aspects of its work from the written and electronic media in the EU and increasingly
from central and eastern Europe and the United States. This interest resulted in sev-
eral radio and television interviews as well as articles in daily, weekly and monthly
journals.
As well as playing a responsive role, the Centre was also proactive, seeking to boost
media interest in its work via the frequent dissemination of news releases on its
activities — the style and content of which were improved during the year (see
below). During 1999, the Centre’s database of media contacts was extensively over-
hauled and currently holds approximately 1 200 contacts. The Centre is now look-
ing to increase its contacts with the youth press and specialised scientific media.
EMCDDA media strategy
In the second half of the year, the EMCDDA commissioned an external expert to
analyse its media relations work from 1996–99 and to propose elements for a com-
prehensive media strategy (contractor: John Wright, United Kingdom).
The analysis examined: the role of the EMCDDA as an information provider for jour-
nalists; the information provided by the EMCDDA; the Centre’s media contacts; the
effectiveness and impact of the Centre’s press releases; the effectiveness and impact
of the press launches of the EMCDDA’s Annual report; and the press coverage of the
1998 Annual report. The analysis was completed in November for submission to the
EMCDDA Management Board and the Reitox network for comments early in 2000.
Impact of the EMCDDA Annual report on the media, decision-
making and public opinion
In October 1999, the Centre contracted an ‘Analysis of the presentation and impact
of the 1998 Annual report’. The final report covers, and offers recommendations on,
issues such as: design; topicality and usefulness; areas covered; language; and the
report’s impact on the media, decision-making and public opinion (contractor:
Alison Roberts, Portugal).
News events
The EMCDDA increased the number of its news events in 1999 marking major 
visits or the release of key reports.
Informal press session with the Presidents of France and Portugal
The first news event of 1999 concluded the visit to the Centre on 4 February of
Presidents Jacques Chirac of France and Jorge Sampaio of Portugal and took the
form of an informal press session. The visit was of particular relevance to the 
EMCDDA in the run-up to the French and Portuguese Presidencies of the Council
of the European Union in 2000.
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Joint EMCDDA-ONDCP news conference
A formal news conference opened the visit to Lisbon of Barry R. McCaffrey, Director
of the United States White House Office of National Drug Control Policy (ONDCP)
on 28 October. Director McCaffrey cited the Centre’s scientific work as ‘an exam-
ple of how the ONDCP could benefit from Europe’s experience in the drugs field’.
Media day launching the EMCDDA 1999 Annual report
On 22 November, the EMCDDA held a media day to launch its 1999 Annual report.
An informal question-and-answer session took place prior to the official press con-
ference in Berlin where selected journalists from each EU Member State and some
central and east European countries (CEECs) exchanged views with the Centre’s
executive director and scientific staff.
The official press conference was held at the Presse- und Informationsamt der
Bundesregierung and was co-organised by the EMCDDA and the German Ministry
for Health. Some 55 German and international journalists from both the written and
broadcast media attended the event and heard presentations by the chairman of the
EMCDDA Management Board and the Centre’s Executive Director. A statement from
the German drugs coordinator, Christa Nickels, was delivered in absentia.
A parallel session was held at the Spokesman’s Service at the European Commission
in Brussels where over 250 journalists received EMCDDA press packs containing
press releases and the report in 11 EU languages.
The EMCDDA distributed two news releases in all 11 languages to the 1 200 jour-
nalists included in its media database prior to the launch. The Reitox national focal
points and European Commission offices in the Member States were also invited to
further disseminate these communications and to follow up media contacts and
coverage nationally.
Press reception for Royal and Presidential visit
On 23 November, King Albert II of the Belgians and Queen Paola, and the President
and First Lady of Portugal visited the EMCDDA. A press reception unit was set up
for the Belgian and Portuguese journalists accompanying the visit where press packs
were distributed along with copies of the 1999 Annual report. Interviews were given
to a number of newspaper and broadcast journalists on the Centre’s activities.
EMCDDA news events, 1999
Date Event
4 February Visit to the EMCDDA of His Excellency President Jacques
Chirac of France and His Excellency President Jorge
Sampaio of Portugal
28 October Visit to the EMCDDA of Barry R. McCaffrey, Director of the
United States White House Office of National Drug
Control Policy (ONDCP)
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22 November Media day launching the 1999 Annual report
• Briefing for selected EU and CEEC journalists on the
Annual report, Berlin
• Official news conference launching the 1999 Annual
report, Berlin
• Parallel presentation of the 1999 Annual report to the EU
press corps, Spokesman’s Service, Brussels
23 November Press reception on the occasion of the visit of the King of
the Belgians and Queen Paola, and the President and First
Lady of Portugal
News releases
In 1999, the EMCDDA produced 14 news releases, nearly doubling the total num-
ber issued the previous year. Recommendations for improving the text and presen-
tation of the Centre’s news releases were given in a proposed media strategy drawn
up in November (see above) and were to be implemented the same month.
EMCDDA news releases, 1999
Date Title
4 February ‘Presidents Chirac and Sampaio to visit the EMCDDA’
(English, French, Portuguese)
12 February ‘EMCDDA welcomes German drugs coordinator to Lisbon’
(English, German)
26 June ‘New draft European action plan to combat drugs:
Promising news for the EMCDDA, says director’
(English)
1 July ‘EMCDDA Management Board re-elects director for five-
year term’
(English)
15 July ‘Commissioner Gradin to meet national drug coordinators
at EMCDDA’
(English)
16 July ‘EMCDDA informal drugs forum on draft European action
plan to combat drugs: Gradin highlights role of national
drug coordinators’
(English)
15 September ‘Council decides new drug 4-MTA should be placed under
control’
(English, German, Portuguese)
61
Chapter 5: Information strategies and communication resources
28 September ‘EMCDDA and Pompidou Group to unite against drugs’
(English)
26 October ‘ONDCP-EMCDDA encounter on drugs’
(English, Portuguese)
8 November ‘EU to step up use of the Internet to spread drugs 
awareness’
(English)
17 November ‘Spotlight on the EU drugs problem: Annual report of the
EU drugs agency’
(11 EU languages)
22 November ‘1999 Annual report on the EU drug problem: 3–5 million
in the EU could have tried heroin. Over 40 million might
have tried cannabis’
(11 EU languages)
29 November ‘How to make Europeans healthier ... save money on drug
treatment ... cut drug crime: Second European Conference
on the Evaluation of Drug Prevention’
(English and French)
7 December ‘EU steps up use of the Internet to spread drugs awareness’
(adapted for ‘Online Information 99’ conference packs)
(English)
News reviews
In addition to the fortnightly press reviews compiled by an external contractor (see
documentation ‘user services’ below), the Centre also produces its own news
reviews recording the results of specific EMCDDA events.
In March 1999, the Centre distributed its 1998 Annual report news review (cover-
ing the launch of the 1998 report) which carried the 110 articles traced. The exer-
cise was repeated following the launch of the 1999 Annual report and the final
review included over 500 articles. During the year, the Centre also compiled 
quarterly press reviews.
Articles published
As in previous years, the Centre regularly contributed articles on its activities to
magazines and newsletters both in Europe and the US and enhanced its profile
through listings in major directories of international organisations.
As a member of the scientific committee of the Spanish journal Revista Proyecto
Hombre since 1997, the EMCDDA continued to provide regular input to this drug-
specialised quarterly. Early in 1999, it established a similar agreement with a sec-
ond Spanish quarterly journal launched in 1998 entitled Trastornos Adictivos. As a
member of the publication’s consultative committee, the Centre provided regular
articles on its latest findings and achievements (17).
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(17) Proyecto Hombre is published by the Spanish NGO Asociación Proyecto Hombre, ISSN 1136-3177.
Trastornos Adictivos is published by the Sociedad Española de Toxicomanías, ISSN: 1575-0973.
In October 1999, the EMCDDA published a special supplement on its work in EUR-
OP News (3/1999), the quarterly newspaper of the Office for Official Publications
of the European Communities. This supplement was published in all 11 EU 
languages and was distributed to 300 000 readers worldwide, including 6 000 
journalists. The supplement is available on-line (http://europ.eu.int/opnews/
399/en/r3.htm).
EMCDDA public website
The EMCDDA’s public website (http://www.emcdda.org) is a key component of the
Centre’s strategy to disseminate reliable, comparable data on the European drugs
phenomenon as broadly as possible. The site complements the EMCDDA’s printed
publications programme by providing fast, easily accessible and comprehensive
information on all aspects of the Centre’s activities, products and partners.
Prior to 1999, the website was fully designed, edited and maintained in-house by
members of the information department. Reflecting its status as an increasingly
important communication and marketing tool, a project was launched in 1999 for
the extensive redesign and restructure of the site in order to enhance its visual
appeal, navigability and speed of access (contractor: ERIN, Luxembourg).
The new site, which was launched in December at the ‘Online Information 99’
exhibition and conference (see above), provides users with rapid access to:
• detailed information on all aspects of the EMCDDA’s history, mandate, activi-
ties and products;
• up-to-date data on drug use in Europe;
• downloadable publications in all 11 EU languages plus full ordering details for
all printed and electronic products;
• free access to the Centre’s specialised databases;
• links to the Reitox national focal points and to other European and interna-
tional drug-information centres;
• all EMCDDA news releases;
• e-mail contacts to all staff members;
• links to a host of drug-related organisations and sites at European and interna-
tional level; and
• a full search facility.
Continually updated, the site also announces job vacancies and calls for tender and
highlights issues of current interest. The site will be further developed, with empha-
sis placed on the increased use of available technology, the addition of information
in other EU languages and the progressive integration of further specialised data-
bases. The Centre welcomes feedback on the new site from its users.
EMCDDA Intranet
In 1999, the Centre established an internal information (institutional and non-insti-
tutional) network (Intranet), exclusively for its staff members. Regularly updated, it
helps staff with their research needs via: specialised news and discussion groups;
provision of useful EU information; press reviews; and administrative information. It
also provides staff members with on-line access to the EMCDDA’s library catalogue.
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Documentation
Implementing phase for a distributed documentary database
(‘Virtual library’)
The ‘Virtual library’ is a pan-European distributed documentary database providing
a selection of documents from existing national databases in a comparable and
standardised format. The library allows bibliographic searches of different sources
to be made on one common database, and prevents duplication and overlap of
information among the EMCDDA and its Reitox partners.
During 1999, the management of the project was transferred from Toxibase (France)
to the EMCDDA. As a result:
• the database was migrated to an EMCDDA server;
• following a study to identify the best configuration for the database, a new
search engine was installed and a new documentary format created;
• a call for tender for an external evaluation of the project was launched to
define how the library could best be developed (contractor: Bureau van Dijk,
Paris); and
• following the evaluation’s recommendations, a work programme was estab-
lished to revise the project strategy and enlarge the number of national centres
participating.
The Reitox ‘Virtual library’ is now available on the EMCDDA public website
(http://www.emcdda.org/databases/databases_virtlib.shtml) with references selected
from the EMCDDA, France, the Netherlands, Norway, Portugal, Sweden and the
United Kingdom.
Other activities in the field of documentation
Development of the library catalogue
During 1999, the EMCDDA’s internal library catalogue, Bibliodatabase, was further
developed both to improve the quality of the service available to users and to rein-
force cooperation with the scientific departments.
Two specialised bibliographies — ‘Literature review on the relation between drug
use, impaired driving and traffic accidents’ and ‘Bibliographic database on
European qualitative research on drugs (QED)’ — prepared by the epidemiology
department and currently containing 1 400 records in a common format, were
added to the bibliodatabase in a new chapter, ‘Thematic bibliographies’. A third
bibliography, ‘Scientific literature on drug-related non-fatal emergencies’, will be
added in 2000.
In addition, a new software package was introduced to help better manage the
structured lists of key words used in indexing. This package can also be used in
future to manage a detailed multilingual thesaurus of specialised terms.
The full library catalogue is available to staff members via the EMCDDA’s Intranet
allowing for on-line consultation and borrowing. In addition, two of its chapters —
‘EMCDDA reports’ and ‘Thematic bibliographies’ — are to be made available to the
general public via the Centre’s public website during 2000.
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User services
During 1999, the EMCDDA’s documentation and information centre developed the
following information services for the staff of the Centre:
• a fortnightly press review tracking media coverage of the Centre and its work
and providing key articles on drug-related matters collected globally (contrac-
tor: Courrier International, France);
• a new Intranet providing the staff with links to:
— internal and European Commission institutional and administrative infor-
mation;
— details of major visits to the EMCDDA and major meetings organised by or
attended by its staff;
— specialised newsgroups with information collected from the European insti-
tutions and major EMCDDA partner organisations; and
• the EMCDDA serials catalogue, available via the Centre’s website
(http://www.emcdda.org/databases/databases_serials.shtml) containing the
most relevant periodical titles held by the documentation centre.
Information technology (IT)
Common EMCDDA-Reitox electronic network
The common EMCDDA-Reitox electronic network, set up with funding from the
European Commission’s interchange of data between administrations (IDA) I pro-
gramme, was increasingly used in 1999 by the Reitox community (EMCDDA and
national focal points) for disseminating and exchanging information and promoting
understanding and transparency within the network (see Chapter 3). During the
year, the Reitox community prepared for the further development of the common
electronic network, including the extension of services and the integration of new
partners. Concrete steps in 2000 will be subject to the availability of funds under
the IDA II project. 
Other activities in the field of information technology
Consolidation of the EMCDDA’s IT environment
To ensure that all members of staff have up-to-date electronic equipment, the
EMCDDA acquired new computers and printers in 1999. It also purchased new
hardware to increase the capacity of its local area network (LAN), including addi-
tional servers and network switches.
To ensure the smooth operation of the Centre’s electronic information services, the
EMCDDA also upgraded its servers over the year. In addition, it has increased the
capacity of the data communications line connecting the EMCDDA to the Internet.
Since the Centre hosts both the public EMCDDA website and the private Reitox
website, increasing the capacity of the Internet connection has enhanced access to
these services for both external and internal users.
One of the major information-technology (IT) tasks in 1999 was to check all IT hard-
ware and software to ensure that they were year 2000 (Y2K) compliant. Where they
were not, they were either replaced, or updates, upgrades or patches were applied.
Simultaneously, the settings on every personal computer (PC) in the Centre were
checked and, where necessary, standardised.
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Being connected to the Internet always increases the risk of exposing the IT infra-
structure to security problems. To minimise this risk, security rules were established
by the IT team. An in-house security policy was drawn up which every member of
staff was required to sign in order to gain access to the local area network as well
as to the Internet. The security policy clearly states what a user is, and is not, per-
mitted to do.
Due to the high risk of infecting the network with viruses when exchanging data
over the Internet, virus checkers have been installed on every PC. These are regu-
larly updated. In addition, a special PC was installed to check all incoming e-mails
for viruses.
To improve the system of sending press releases to the EMCDDA’s media contacts,
a new fax server was installed which is now scalable and well integrated into the
existing server infrastructure.
Participation in projects
Apart from reinforcing the Centre’s telematics infrastructure, members of the IT team
have also acted as technical advisers or project leaders for many EMCDDA projects
involving software development or as consultants on projects concerning IT infra-
structure. These projects include:
• the exchange on drug demand-reduction action (EDDRA) information system
(see Chapter 2);
• the information system on training activities in the field of demand reduction
(ISTRA) (see Chapter 2);
• the evaluation instrument bank (EIB) (see Chapter 2);
• the budgetary and financial system (SI2) (see Chapter 6);
• the EMCDDA public website;
• the Reitox website;
• the EMCDDA Intranet;
• the web interface for the Centre’s library catalogue;
• the automatic distribution of e-mails into newsgroups;
• the migration of the ‘Virtual library’ from Toxibase to the EMCDDA;
• preparation for the creation of a legal database on drugs;
• ‘Year 2000’ (Y2K) compliance of the Centre’s IT infrastructure;
• the Centre’s mail management system (Adonis);
• TESTA;
• IDA II; and
• the European website and network for qualitative research
(http://www.qed.org.uk).
Major meetings organised by the EMCDDA, 1999
Information strategies and communication resources
Date Place Event
Documentation
4–6 November Lisbon 11th annual meeting of the European
Association of Libraries and Information
Services on Alcohol and other Drugs
(ELISAD)
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Major meetings attended by the EMCDDA, 1999
Information strategies and communication resources
Date Place Event
Documentation
20–22 January Paris EMCDDA-Toxibase meeting on the Reitox
‘Virtual library’
4 June Lausanne EMCDDA-ELISAD preparatory meeting for
the 11th annual meeting of the European
Association of Libraries and Information
Services on Alcohol and other Drugs 
Publications
18–19 March Luxembourg EMCDDA-EUR-OP meeting on the 1998
Annual report and other publications issues,
EUR-OP
30 April Brussels Seventh meeting of the European Union
Publishers’ Forum
26–28 July Luxembourg EMCDDA-EUR-OP meetings on general
publications issues, EUR-OP
7–8 September London EMCDDA-UK focal point meeting on the
and Brighton production of the 1999 Annual report 
9–10 September Luxembourg EMCDDA-EUR-OP meeting on the graphic
presentation of EMCDDA publications and
press preparations for ‘Online Information
99’, EUR-OP
21–23 September Luxembourg Preparatory meeting for EU participating ser-
vices in ‘Online Information 99’, EUR-OP
13–15 October Frankfurt Frankfurt Book Fair, EUR-OP
14 October Frankfurt Eighth meeting of the European Publishers’
Forum
Media relations
22 November Berlin EMCDDA-German Ministry of Health:
launch of the Annual report on the state of
the drugs problem in the European Union
1999
6–9 December London ‘Online Information 99’, organised by
Learned Information, United Kingdom 
Website
6–9 December London ‘Online Information 99’
28 July Luxembourg Project meeting ERIN
22 September Luxembourg Project meeting ERIN
Information technology
18–24 March Hanover CEBIT 99 international computer workshop
22 April Brussels Tutorial on TESTA statistics, Global One
4 May Brussels TESTA user group meeting, Directorate-
General for Enterprise of the European
Commission
6–9 May Turin Technical meeting on SI2, European Training
Foundation (decentralised EU agency)
17 May Brussels Third meeting of the inter-agency steering
committee: SI2 common support service 
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26–27 May Brussels Preparatory meeting for the IDA II-Reitox
project, Directorate-General for Enterprise 
9–11 June Paris Conference on new Intranet and Internet
tools and applications, Online Information,
France
3–4 July Luxembourg Visit to the Translation Centre for the Bodies
of the European Union in the context of the
EDDRA project
9 September Luxembourg Meeting on Internet environment and tools,
ERIN
10 September Luxembourg Technical coordination meeting of the
EDDRA project, Luxembourg national focal
point
10 September Brussels Final meeting of the IDA-Reitox project,
Directorate-General for Enterprise
Other
19–23 March Luxembourg Meeting of the Management Board of the
Translation Centre for the Bodies of the
European Union
10–12 May Brussels EMCDDA-European Commission Drugs Coor-
dination Unit: meeting on the dissemination
of information, Brussels
1 October Luxembourg Meeting of the Management Board of the
Translation Centre for the Bodies of the
European Union
Articles published, 1999
Information strategies and communication resources
Media relations
‘OEDT: Para ponerle al corriente sobre el fenómeno de las drogas en Europa’,
Trastornos Adictivos, Journal of the Sociedad Española de Toxicomanías, 
Vol. 1. No 1, 1999, p. 66.
Robertson, K., ‘Detecting and controlling new synthetic drugs’, feature article
for Interpol’s website (http://193.123.144.14/interpol-pr), January 1999
Robertson, K., ‘EMCDDA: Putting you in the picture on drugs in Europe’, SALIS
News, International Newsletter of Alcohol, Tobacco and other Drug Librarians
and Information Specialists, Vol. 18, January 1999, pp. 4–5.
Robertson, K., ‘EMCDDA: The hub of drug information in Europe’, Special fea-
ture on Drugs, EISS News, Newsletter of the European Institute of Social
Services (EISS), No 18, February 1999, pp. 15–17.
Robertson, K., ‘Informe Annual 1998’, Revista Proyecto Hombre, No 29,
March 1999, pp. 25–26.
Robertson, K., ‘What difference does the European Union make to the drug
problem in Europe?’, Social Work in Europe, Vol. 6, No 2, pp. 33–38.
Special supplement on the EMCDDA, EUR-OP News, No 3, Autumn 1999. 
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Chapter 6
Administration, finance
and logistics
Following the re-examination of the EMCDDA’s administrative structure
and financial procedures in 1998, attention was focused in 1999 on
evaluation. 
This took the form of an external evaluation of the EMCDDA and its
activities in the latter half of the year, aimed at providing a broad-based
description and analysis of the agency, its modus operandi and
achievements (18). 
The results of this procedure, which were being drawn up at the end of
the year and which are due for completion in spring 2000, are expected to
play a major role in the Centre’s work and decision-making processes in
the coming years.
(18) Management consultants Deloitte & Touche embarked on the external evaluation of the Centre in July
1999 following a call for tender launched by the EMCDDA and the European Commission earlier in the
year.
Administration
EMCDDA staff
Five new posts were created under the 1999 budget: three posts at A7/A6 level 
and two posts at B5/B4 level. At the end of 1999, a total of 51 statutory staff mem-
bers (3 European Union officials, 38 temporary agents, 9 auxiliary agents and 1 sec-
onded national expert) were employed at the EMCDDA along with 11 local agents.
The table below indicates the nationality, status and grade of the staff members.
Employees of the EMCDDA share the same status as their colleagues in other
European Community agencies, being subject to the ‘Staff regulations and rules
applicable to officials and other servants of the European Communities.’
EMCDDA staff breakdown by nationality, status and grade 
Nationality EU official Temporary Auxiliary Seconded Total
staff staff national
expert 
A B C A B C A B C A B C
Belgium 1 2 1 1 3 8
Denmark 1 1
Germany 2 1 1 1 5
Greece 1 1
Spain 1 2 1 1 1 6
France 4 3 7
Ireland 0
Italy 2 1 3
Luxembourg 1 1
Netherlands 1 1
Austria 0
Portugal 1 4 4 1 1 11
Finland 0
Sweden 1 1 2
United 
Kingdom 5 5
Total 2 1 0 21 9 8 3 1 5 1 0 0 51
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Finance
Key decisions
In 1999, key financial decisions taken by the EMCDDA Management Board 
included:
• decision to give the director discharge on the implementation of the 1997
budget;
• adoption of the 1999 budget broken down into EUR 7 800 000 in EU annual
funding (budget line B3-441) and EUR 255 600 in a European Commission
financial contribution relating to the Centre’s participation in a specific project
under the EC targeted socioeconomic research (TSER) programme;
• adoption of the EMCDDA’s 2000 preliminary draft budget of EUR 8 800 000;
• decision to adopt a supplementary and amending 1999 budget in order to
include the EUR 450 000 transferred by the European Parliament on 22 April
from budget line B5-900 (reserve for decentralised agencies) to budget line
B3-441 (EU annual funding for the EMCDDA budget) bringing the total bud-
get for 1999 to EUR 8 505 600.
EMCDDA 1999 budget
The budgetary figures for 1999 are presented in the tables below.
Budgetary provisions and appropriations, 1999
Title Description EUR
1. Staff 
• Staff salaries, allowances, insurance, training 3 376 000
• Missions 200 000
• Other staff-related expenditure (socio-medical 
infrastructure, exchange of officials, etc.) 84 000
Total under Title 1 3 660 000
2. Buildings, equipment and sundry operating expenditure
• Investment in property, letting of property and incidental costs 175 500
• Information technology 120 000
• Goods, furniture and incidental costs 286 000
• Standard administrative functioning 102 000
• Postage and telecommunications 106 500
• Statutory meetings 185 000
Total under Title 2 975 000
3. Operating expenditure
• Costs of convening meetings 350 000
• Studies, surveys, consultations and training 735 000
• Publications 740 000
• Support for the Reitox network 1 790 000
Total under Title 3 3 615 000
Total core budget 8 250 000
4. Expenditure relating to other subsidies
• EC financing of specific projects 255 600
10. Other expenses (reserve) 0
Total budget 8 505 600
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Execution of the budget: Credit consumption, 1999
(Commitments)
Title Description % consumption of 
available credits
1. Staff
• Staff salaries, allowances, missions, etc. 97
2. Buildings, equipment and sundry operating expenditure 91
3. Operating expenditure 94
4. Expenditure relating to other subsidies 100
Total consumption (Titles 1, 2, 3 and 4) 95
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EMCDDA balance sheet for the financial years
1998 and 1997: Assets
(1 000 EUR)
Assets 1998 1997
Fixed assets
• Fixed assets 3 518 3 409
Subtotal 3 518 3 409
Stocks
• Office equipment 29 12
Subtotal 29 12
Current assets
• Commission subsidy 570 2 668
• Sundry debtors 403 207
• Payments on specific subsidies (19) 10 0
• VAT to be recovered 4 172
Subtotal 987 3 047
Cash accounts
• Bank 3 230 1 209
• Imprest account 527 800
• Transfers in progress – 47 – 1 820
• Cash accounts 0 1
Subtotal 3 710 190
Total assets 8 244 6 658
EMCDDA balance sheet for the financial years
1998 and 1997: Liabilities
(1 000 EUR)
Liabilities 1998 1997
Fixed capital
• Own capital (20) 3 547 3 421
• Balance for the financial year 1 287 – 1 569
Subtotal 4 834 1 852
Current liabilities
• Commission subsidy 570 2 668
• Non-automatic carry-overs 
of appropriations 280 0
• Automatic carry-overs 
of appropriations 2 112 1 930
• Sundry accounts due 405 21
• VAT 4 172
• VAT re-use accounts 39 15
Subtotal 3 410 4 806
Total liabilities 8 244 6 658
(19) Appropriations allocated on the basis of specific subsidies (various seminars).
(20) The amount corresponds to that of fixed assets and stocks excluding the refurbishing of the building
(about EUR 1 million).
Chapter 6: Administration, finance and logistics
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Out-turn account
Revenue and expenditure for the financial years 1998 and 1997 
(1 000 EUR)
1998 1997
Revenue
• Commission subsidy 9 695 3 632
• Miscellaneous revenue 154 90
• Bank interest 123
Total revenue 9 972 3 722
Expenditure 
• Title I: Staff
— Payments 2 751 2 517
— Appropriations carried forward 138 6
• Title II: Buildings, equipment 
and sundry operating expenditure
— Payments 805 884
— Appropriations carried forward 430 43
• Title III: Operating expenditure 
— Payments 1 305 829
— Appropriations carried forward 1 544 1 881
— Non-automatic carry-overs 280 0
Total expenditure 7 253 6 160
Out-turn for the financial year 2 719 – 2 438
• Balance carried over from the previous year – 1 569 885
• Adjustment to out-turn from previous year (21) 0 – 81
• Appropriations carried forward and cancelled 137 92 
• Exchange-rate differences 0 – 27 
Balance for the financial year 1 287 – 1 569 
Logistics
In June, the Bureau of the EMCDDA Management Board requested the Centre to
analyse, in consultation with an architect, its real-estate requirements as have arisen
out of insufficient workspace and inadequate infrastructure at EMCDDA head-
quarters. In October, the Centre was advised on how to meet these needs. 
Various options were analysed.
(21) Amount included in the subsidies to be received under the financial year 1997 but subsequently 
not collected. 
The EMCDDA
and its statutory bodies
The EMCDDA’s statutory bodies are the 
Management Board, the 
Bureau of the Management Board and the 
Scientific Committee 
all of which met in 1999. 
A summary of the decisions adopted and major points discussed 
at their meetings are set out in the following pages.
Chapter 7
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Management Board
The Management Board is the main decision-making body of the EMCDDA. It
meets at least once a year and consists of one representative of each Member State
of the European Union, two representatives of the European Commission and two
persons highly qualified in the field of drugs designated by the European Parliament.
In 1999, the Management Board met three times in Lisbon. Besides its usual 
agenda items — such as the adoption of the annual work programme and budget
— it re-elected the EMCDDA’s Director, Georges Estievenart for a second five-year
term. The Committee met on all three occasions under the chairmanship of Franz J.
Bindert (Germany).
Management Board meetings in 1999
At its 15th meeting in Lisbon on 14 and 15 January, the Management Board 
adopted, among others: the 1999 work programme; the General report of activities
1998; a budget of EUR 7.8 million for 1999; and a preliminary draft budget of 
EUR 8.8 million for 2000. In the context of the EU pre-accession strategy and in the
framework of collaboration between the EMCDDA and the European Commission,
the Board also assigned the Centre a more active role in cooperation with the 
central and east European countries (CEECs).
In addition to these decisions, the Management Board discussed: the proposed cre-
ation of an EMCDDA legal information system on drugs; relations between the
Centre and international organisations; and negotiations concerning the participa-
tion of Norway in the EMCDDA’s activities. The chairman presented to the meeting
the agency’s newly published Report on the risk assessment of MBDB in the frame-
work of the joint action on new synthetic drugs.
At its 16th meeting from 30 June to 2 July, the Management Board: re-elected the
director for a second five-year term (from 23 December 1999); decided to launch
the first phase of the EMCDDA legal information system on drugs; and agreed to
conclude memoranda of understanding with the Council of Europe (Pompidou
Group) and the World Health Organisation (WHO). Furthermore, the Board 
adopted draft resolutions on: the ongoing negotiations with Norway, and with third
countries in general; and the EMCDDA’s participation in the European
Commission’s Phare multi-beneficiary drugs programme. A supplementary budget
of EUR 450 000 for 1999 was adopted at the meeting (see Chapter 6).
In addition to these decisions, items discussed included: relations between the
EMCDDA and international organisations; implementation of the Centre’s five har-
monised key epidemiological indicators; and the evaluation of the EMCDDA by
external consultants. The Board also heard: the Director’s proposed medium-term
perspectives for the agency (2000–04); a presentation on a pilot project to estimate
time trends and the incidence of the drug use problem in the EU; and the findings
of a study on concepts, practice and terminology in outreach work among drug
users in Europe. The chairman presented to the meeting the agency’s newly pub-
lished Report on the risk assessment of 4-MTA in the framework of the joint action
on new synthetic drugs.
At its 17th meeting on 28 and 29 October, the Management Board adopted a 
decision to launch a study on the prosecution of drug users and discussed, 
among others, the draft 2000 work programme and the EMCDDA’s medium-term
perspectives (2000–04).
Bureau
The Bureau of the Management Board meets five to six weeks before each
Management Board meeting to prepare the agenda for the latter in consultation with
the director. In accordance with Article 2 of Council Regulation (EEC) No 302/93,
the Bureau may also, between any two meetings of the Board and in consultation
with the director, take decisions unanimously which are urgent or necessary for the
management of the Centre, subject to ratification by the Board at its next meeting.
In 1999, the Bureau met five times in Lisbon and once in Brussels (22).
Bureau meetings in 1999
In the course of the year, issues discussed by the Bureau included: the external eval-
uation of the Centre and the work of the special EMCDDA steering group set up to
accompany the evaluators; the limitations and suitability of the current EMCDDA
headquarters; the launch of the 1999 Annual report; and the timetable for the pro-
duction of the 2000 Annual report.
In March, the Bureau prepared a meeting between the EMCDDA, the then chair-
person of the European Parliament’s Committee for Civil Liberties and Internal
Affairs (now the Committee on Citizens’ Freedoms and Rights and Home Affairs) and
selected Members of the European Parliament on the activities of the Centre and the
Reitox focal points.
Scientific Committee
The Scientific Committee is a consultative organ that assists the Management Board
and the EMCDDA with its opinions and recommendations on scientific matters. The
Committee consists of one representative from each of the Member States of the
European Union, although the Management Board may elect up to six other mem-
bers. The Committee is convened by its chairman at least once a year.
In 1999, the Scientific Committee met three times in Lisbon, holding two regular
meetings and one extended meeting in the framework of the joint action on new
synthetic drugs. The Committee met on all three occasions under the chairmanship
of Desmond Corrigan (Ireland).
Scientific Committee meetings in 1999
The 11th meeting of the EMCDDA Scientific Committee, on 17 and 18 May, dis-
cussed implementation of the 1999 work programme and the contribution of the
Scientific Committee to the EMCDDA’s 1999 Annual report. It also created two sub-
committees (composed of Scientific Committee members) responsible for assisting
and advising the EMCDDA in improving the quality of epidemiological and
demand-reduction data and studies. Furthermore, it discussed the findings of the
steering group meeting of 17 May on 4-MTA and on the follow-up to the risk-assess-
ment report on MBDB (see below).
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(22) 15 March; 7 May; 30 June; 16 September (Brussels); 28 October; 6 December.
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On 18 and 19 May, an enlarged EMCDDA Scientific Committee met to assess the
risks of 4-MTA. This special risk-assessment meeting was attended by Scientific
Committee members, additional experts from the Members States, representatives of
the European Commission, the European Agency for the Evaluation of Medicinal
Products (EMEA) and Europol. The enlarged Committee’s tasks were to assess the
health and social risks of the substance and the possible consequences of prohibi-
tion. The meeting resulted in the formal adoption on 19 May of a ‘Report on the risk
assessment of 4-MTA in the framework of the joint action on new synthetic drugs’.
This report, presented to the Council of the EU and the European Commission on
24 May concluded that 4-MTA should be placed under control in the Member States
largely due to the high risks of overdose associated with the drug.
At the 12th meeting of the EMCDDA Scientific Committee on 6 and 7 December,
the members adopted a favourable opinion on the EMCDDA’s 2000 draft work pro-
gramme and discussed the proposed medium-term perspectives for the EMCDDA
(2000–04). Updated information was presented on MBDB, 4-MTA, Ketamine and
GHB as were the findings of a technical evaluation meeting held on 29 November
to prepare a short list of toxicity-testing laboratories within the EU (see Chapter 4).
Furthermore, the meeting heard the findings of the two subcommittees on the quality
indicators for epidemiological and demand-reduction studies.
Steering group meetings
The Scientific Committee’s steering group — set up in 1997 to prepare the risk-
assessment procedure under the joint action on new synthetic drugs — met five
times in 1999 (see also Chapter 4).
On 19 April, a high-level expert meeting on the pharmacotoxicology of 4-MTA was
held at the EMCDDA and attended by experts and steering group members. 
A scientific literature review on the substance and its incidence was presented.
The meeting on 17 May prepared the extended Scientific Committee meeting on 
4-MTA. Discussions also centred on progress regarding measures to improve future
risk-assessment cases as stated in the report on MBDB. The meeting heard a
progress report on the establishment of an inventory of toxicity-testing laboratories
within the EU for providing relevant data on new synthetic drugs. Also discussed
was the importance of rapidly disseminating harm-reduction information to (poten-
tial) users through the early-warning system on new synthetic drugs, provided under
the joint action, once a new substance has been detected. The meeting on 19 May
finalised the ‘Report on the risk assessment of 4-MTA in the framework of the joint
action on new synthetic drugs’.
The steering group meetings of 30 November (also attended by external experts) and
7 December focused on improving risk-assessment methodology (further develop-
ing the risk-assessment guidelines) through criteria for allocating scores and weight-
ing evidence.
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The EMCDDA
and its partners
Since its creation, the EMCDDA has developed partnerships with a wide
range of organisations, both within the European Union and further afield.
In addition to its contacts with the European institutions and agencies, it
has established contacts with six international partners: the Council of
Europe’s cooperation group to combat drug abuse and illicit trafficking
(Pompidou Group); the United Nations International Drug Control
Programme (UNDCP); the World Health Organisation (WHO); the European
Police Office (Europol); the International Criminal Police Organisation
(Interpol); and the World Customs Organisation (WCO). 
The EMCDDA participates as an observer in the meetings of the permanent
correspondents of the Pompidou Group, those of the UNDCP’s Commission
on Narcotic Drugs (CND), and in Interpol’s General Assembly. The
Pompidou Group, UNDCP and the WHO also participate as observers in the
Centre’s Management Board meetings.
In 1999, the Centre furthered existing cooperation while establishing links
with new bodies and regions. Work in this area was largely undertaken by
a new section attached to the director’s office responsible for new
synthetic drugs, international cooperation and legal information. 
However, all departments were involved in these contacts to a certain
degree.  
Cooperation with European Union institutions and bodies
European Parliament
Early in 1999, the EMCDDA followed discussions in the European Parliament
regarding the EU drug phenomenon, in general, and the development of the
European Union drugs strategy (2000–04), in particular. The discussions took place
in the Committee on Citizens’ Freedoms and Rights, Justice and Home Affairs (the
former Committee on Civil Liberties and Internal Affairs).
During its plenary session from 15 to 19 November, the Parliament adopted a for-
mal opinion on the strategy, following the conclusion of a report on the subject by
the new Committee (Final A5-0063/1999. Rapporteur: Marietta Giannakou-
Koutsikou). This report, welcoming the strategy, underlines the lack of, but need for,
comparable data on drugs in the EU, based on common definitions and concepts.
It calls for an EMCDDA budget commensurate to its tasks and for an annual exam-
ination of the Centre’s progress in implementing a global drug information system.
The agency is complimented in the text on its achievements in the field of new syn-
thetic drugs and the evaluation of drug prevention.
Council of the European Union
In 1999, the EMCDDA participated as a permanent observer in the Horizontal
Drugs Group (HDG) of the Council of the European Union. This participation 
largely related to: implementation of the 1997 joint action on new synthetic drugs;
development of the European Union drugs strategy (2000–04); and the European
Union’s international relations. The Centre also attended as an observer a number
of meetings of the Council’s ‘Illegal Drugs Trafficking Working Party’ established in
the context of the third pillar of the Maastricht Treaty on European Union (cooper-
ation in the field of justice and home affairs).
European Commission
Informal drugs forum
An informal drugs forum, organised by the EMCDDA in cooperation with former
European Commissioner responsible for justice and home affairs, Anita Gradin, was
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1998–2000 work programme
The EMCDDA and its partners, activities in 1999
Priority objective 5
Developing structured cooperation with the EMCDDA’s international partners
and ensuring synergies and complementarity with EU programmes and activi-
ties, avoiding any duplication of work
Cooperation with European Union institutions and bodies
Cooperation with European and international partners
Cooperation with central and east European countries (CEECs)
Developing cooperation with third countries
held in Lisbon on 16 July to discuss the European Union drugs strategy (2000–04).
Mrs Gradin stressed the important role of the EU Member States’ national drug coor-
dinators in the implementation of the strategy ‘in view of their unique overview of
individual national drug strategies and policies’. Mrs Gradin also commented on the
importance of reliable and comparable information on drugs. She applauded efforts
made by the EMCDDA to bridge the differences between existing information sys-
tems in the Member States, which had contributed to a much-improved overview of
the drug situation in the EU.
Directorate-General for Justice and Home Affairs
In preparation for the Annual report on the state of the drugs problem in the
European Union 1999, the Drugs Coordination Unit of the European Commission’s
Directorate-General for Justice and Home Affairs provided the EMCDDA with
details regarding EU action in the field of drugs. At the invitation of the Unit, the
EMCDDA also contributed to the drafting of the European Union drugs strategy
(2000–04).
Directorate-General for Enterprise
For details on the interchange of data between administrations (IDA) programme,
see Chapter 5.
Directorate-General for Health and Consumer Protection
The EMCDDA cooperated with the Directorate-General for Health and Consumer
Protection in the organisation of the second European Conference on the Evaluation
of Drug Prevention, held under the auspices of the EMCDDA and the European
Commission from 2 to 4 December in Strasbourg (see Chapter 2). Furthermore, the
directorate-general nominated a Commission ‘EDDRA manager’ who participated
in the Centre’s EDDRA coordination meetings with a view to introducing EU-eval-
uated projects into the database. In the area of epidemiology, the Centre presented
information on its five key indicators at the ‘fifth meeting of the Committee for the
programme of Community action on health monitoring’ organised by the direc-
torate-general on 4 May in Luxembourg (see Chapter 1).
Directorate-General for Transport
The EMCDDA maintained contacts with the Directorate-General for Transport on
the topic of drugs and driving.
Directorate-General for Research
In 1999, the EMCDDA received funding from the European Commission’s targeted
socioeconomic research (TSER) programme for a number of projects in the field of
epidemiology (see Chapter 1). The Centre also participated in information exchange
in the framework of the Commission’s fifth framework programme (1998–2002),
which defines the EU’s strategic priorities for research, technological development
and demonstration activities.
Eurostat
The EMCDDA cooperated closely with Eurostat on the topic of drug-related deaths
(see Chapter 1).
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European Union agencies
The EMCDDA participated in several meetings of the EU decentralised agencies,
and contributed to discussions on the impact of the future participation of the CEEC
candidate countries on their work (see footnote 16). Cooperation was enhanced
with the London-based European Agency for the Evaluation of Medicinal Products
(EMEA) in the framework of the joint action on synthetic drugs.
Cooperation with European and international partners
Council of Europe cooperation group to combat drug abuse and
illicit trafficking (Pompidou Group)
A memorandum of understanding (MOU) formally establishing cooperation
between the EMCDDA and the Council of Europe (Pompidou Group) was con-
cluded in Strasbourg on 28 September. The agreement was signed by the recently
appointed Secretary-General of the organisation, Walter Schwimmer, and EMCDDA
Executive Director, Georges Estievenart. The MOU will help enhance the exchange
of information and expertise between the two bodies and improve the coordination
and planning of their respective work programmes, avoiding duplication of effort.
Head of the Pompidou Group secretariat, Christopher Luckett, discussed imple-
mentation of the MOU with the EMCDDA director on 9 November during a visit to
the Centre.
The EMCDDA participated as an observer in the 43rd and 44th meetings of the per-
manent correspondents of the Pompidou Group (28 to 30 April and 4 to 5
November) in Strasbourg. The Pompidou Group participated in the Management
Board meetings of the EMCDDA as well as in the second European Conference on
the Evaluation of Drug Prevention organised by the EMCDDA and the European
Commission in Strasbourg from 2 to 4 December.
United Nations International Drug Control Programme (UNDCP)
UNDCP Executive Director, Pino Arlacchi, visited the EMCDDA on 30 September
to discuss implementation of the memorandum of understanding signed between
the two bodies on 13 March 1998. The talks covered cooperation in areas such as:
harmonised indicators; exchange of legal information; new synthetic drugs; and
national reporting. Mr Arlacchi applauded the EMCDDA’s ongoing work in the
development of the five epidemiological indicators of drug trends in the EU and 
stated that Europe was in a privileged position to create ‘the nucleus for a standard
setting for measuring drug demand’.
The EMCDDA participated as an observer in 1999 in the meetings of the
Commission on Narcotic Drugs (CND).
World Health Organisation (WHO)
A draft memorandum of understanding between the EMCDDA and the WHO was
prepared in 1999. Signature of this agreement, likely to take place in March 2000,
would boost cooperation between the organisations with the aim of: improving the
collection and analysis of data; developing and promoting data-comparison 
methods; and intensifying the dissemination of information.
In 1999, the Centre continued its cooperation with the WHO on the project
‘Evaluation of the treatment of substance use disorders’ (see Chapter 2).
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European Police Office (Europol)
Cooperation between the EMCDDA and Europol increased in 1999 due to their
shared role in the joint action on new synthetic drugs (see Chapter 4) (23). An annual
meeting between the two bodies in the framework of the joint action was held at
Europol headquarters on 15 October in The Hague.
At the meeting, the agencies identified areas of work in the field of data collection
and the development of harmonised indicators. As regards law-enforcement indica-
tors, a first division of labour was established. On the one hand, Europol would
focus on seizures and price/purity indicators while the EMCDDA would continue to
act as an ‘EU clearing house’ for all drug-related indicators and statistical data pro-
duced by other international organisations and bodies. A draft memorandum of
understanding (MOU) between the two agencies was discussed at the meeting.
Europol’s legal service will analyse the feasibility of the potential agreement. In the
meantime, cooperation instruments already created under the joint action on new
synthetic drugs will be strengthened.
International Criminal Police Organisation (Interpol)
The EMCDDA and Interpol increased cooperation in 1999, which could pave the
way for the signing of a memorandum of understanding between the two bodies in
the course of 2000.
World Customs Organisation (WCO)
As in previous years, the WCO contributed to the EMCDDA’s 1999 Annual report.
Inter-American Drug Abuse Control Commission (CICAD)
The EMCDDA attended CICAD’s 25th and 26th regular meetings held from 3 to 7
May in Washington DC (US) and from 4 to 7 October in Montevideo (Uruguay). The
central focus of these meetings was the multilateral evaluation mechanism (MEM),
an evaluation mechanism established by CICAD to strengthen mutual confidence,
dialogue and cooperation between countries in the Americas. The MEM was for-
mally adopted in Uruguay and the first round of country-evaluation initiatives
should begin in 2000.
Jean Fournier, Deputy Solicitor-General of Canada and President of CICAD’s multi-
lateral evaluation mechanism working party visited the EMCDDA on 
27 September and presented progress on the development of the MEM. Developing
a framework for greater EMCDDA-CICAD collaboration was also discussed. This
will be further developed in 2000.
Financial Action Task Force on Money Laundering (FATF)
The EMCDDA took part in meetings of the Financial Action Task Force on Money
Laundering (FATF) of the Organisation for Economic Cooperation and Development
(OECD). The Centre participated in meetings on ‘Estimating the magnitude of drugs
proceeds’ in Oporto (Portugal) and The Hague (the Netherlands) on 28 September
and 5 November respectively. The EMCDDA presented the state of the art in data
collection on drug consumption in the EU. Further cooperation will be established
with the FATF in partnership with Europol and the Pompidou Group.
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(23) The joint action grants equal responsibility to the EMCDDA and Europol for establishing an early-
warning system to collect and exchange information on the production, traffic and use of new 
synthetic drugs, taking into account the respective mandates of the two bodies.
Cooperation with central and east European countries (CEECs)
Phare multi-beneficiary drugs programme
Phare project on drug information systems 
Cooperation between the EMCDDA and the central and east European countries
(CEECs) has, in recent years, taken place in the framework of the Phare project on
drug information systems (Phare-DIS) which completed its third and final phase in
March 1999. The final seminar of the Phare-DIS project was held at the EMCDDA
from 15 to 16 February. Discussions focused on the progress achieved by the pro-
ject since 1993 in developing drug-information systems in the CEECs. The project
focused on building a human network of drug experts in the CEECs along with a
supporting technical network.
The European Commission drew up a nine-month bridging contract (EUR 300 000)
in the second half of 1999 with the Phare-DIS project to prepare a possible transfer
of the project’s activities to the EMCDDA. In the framework of its cooperation with
the region, the EMCDDA assists the CEECs in applying its guidelines for the pro-
duction of national reports. Bilateral feedback will be provided by the EMCDDA on
the quality of the national reports, which will be synthesised and utilised in the
EMCDDA’s 2000 Annual report. The reports will provide the basis to assess future
cooperation between the CEECs and the EMCDDA.
Phare project on technical assistance to drug demand reduction
The EMCDDA participated in the evaluation of the Phare project on technical assis-
tance to drug demand reduction (see Chapter 2).
Enhanced pre-accession strategy
Under the terms of the enhanced pre-accession strategy preparing for the adhesion
of the candidate countries to the EU, the Council of the European Union decided to
allow the CEE candidate countries to participate in selected Community pro-
grammes and the activities of some European agencies. Priority was given to the
EMCDDA and the Copenhagen-based European Environment Agency (EEA).
During the year, the European Commission prepared a mandate for negotiation on
behalf of the Council to which the EMCDDA provided comments and proposals at
the request of the Commission in July. The EMCDDA also presented, at the
Commission’s request, a first estimate of the impact of the participation of the CEEC
candidate countries on the work programme, budget and the human resources of
the Centre.
Developing cooperation with third countries
Norway
A proposal to allow Norway to participate in the activities of the EMCDDA was
transmitted to the Council of the EU and to the European Parliament in May 1999.
This proposal foresees full participation of Norway in the Centre’s work.
Latin America
The European Union, Latin America and Caribbean Summit took place in Rio de
Janeiro on 28 and 29 June, with the participation of the Heads of State or
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Date Visit
Cooperation with the European Union institutions and bodies
3 June Visit of Klaus Ebermann, Director at the Secretariat-General
of the European Commission
11 June Visit of Matti Bäckman, Chairman of the Horizontal Drugs
Group, Finnish Presidency
16 July Visit of Anita Gradin, former European Commissioner for jus-
tice and home affairs, on the occasion of an informal drugs
forum
Cooperation with European and international partners
30 September Visit of Pino Arlacchi, Executive Director of the United
Nations International Drug Control Programme (UNDCP)
9 November Visit of Christopher Luckett, Head of the Pompidou Group
secretariat, and Klaus Fuchs, Principal Administrator
Cooperation with the central and east European countries
15–16 February Final seminar of the Phare project on drug information sys-
tems, hosted by the EMCDDA
13 December Visit of Vladimir Shopov, Counsellor for justice and home
affairs of the Mission of the Republic of Bulgaria to the
European Communities 
Developing cooperation with third countries
23 February Visit of David Beall, Executive Secretary of the Inter-
American Drug Abuse Control Commission (CICAD)
14 September Visit of John Carnevale, Director, Office of Programmes,
Budget, Research and Evaluation, United States White
House Office of National Drug Control Policy (ONDCP)
27 September Visit of Jean Fournier, Deputy Solicitor-General of Canada
and President of the CICAD Multilateral Evaluation
Mechanism Working Party 
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Government of the three regions. The EMCDDA and Europol participated in the
preparatory process of the ‘Coordination and cooperation mechanism between the
European Union, Latin America and the Caribbean — Comprehensive action plan
on drugs’, formally adopted at the meeting. In general terms, the mechanism is
designed to deepen political will and technical dialogue between the regions and
to enhance and develop existing cooperation on drugs.
United States
Director of the United States White House Office of National Drug Control Policy
(ONDCP), Barry R. McCaffrey, visited the EMCDDA on 28 October. On this occa-
sion, Director McCaffrey met the EMCDDA’s Management Board where the drug
situation and new policy developments in the US and in the EU were discussed. The
visit was Director McCaffrey’s second to the Centre following his trip to Lisbon in
July 1998 for the first informal US-EU Drugs Forum.
Major visits to the EMCDDA, 1999
28 October Visit of Barry R. McCaffrey, Director of the United States
White House Office of National Drug Control Policy
(ONDCP)
8 November Visit of Walter Fanganiello Maierovitch, General Secretary,
National Secretariat against Drugs, Brazil
9 November Visit of Ambassador of Colombia to Portugal, Jorge Perdomo
Martínez 
Other visits and meetings
8 January Visit of Nicole Maestracci, President of the French Mission
Interministérielle de Lutte contre la Drogue et les
Toxicomanies (MILDT)
4 February Visit of Presidents Jacques Chirac of France and Jorge
Sampaio of Portugal
11 February Visit of Christa Nickels, Parliamentary Under-Secretary of
State for Health, Germany (German Drugs Coordinator)
7 April Visit of the Committee on Hygiene and Health of the High
Chamber (Senato) of the Italian Parliament
23 April Visit of a delegation of the Swedish Ministry of Justice
10 May Visit of Monika Knoche, Member of the German Parliament
26 May Visit of Mike Trace, UK Deputy Drugs Coordinator
10 September Visit of the Swedish Parliamentary Committee for Legal
Affairs
16 September Visit of a Norwegian delegation of NGOs, political, police
and youth organisations
15 November Visit of members of the Joint Committee on European Affairs
of the Irish Parliament
17 November UNDCP-EMCDDA working meeting on legal information
systems
18 November Visit of Ueli Löcher, Vice-Director, Swiss Federal Office for
Public Health
23 November Visit of their Majesties King Albert II of the Belgians and
Queen Paola and President Jorge Sampaio and the First Lady
of Portugal
Major meetings attended by the EMCDDA, 1999
Date Place Event
Cooperation with the European Union institutions and bodies
January–December Brussels Meetings of the Horizontal Drugs Group of the
Council of the European Union
19 February Brussels Meeting of the EU decentralised agencies
16 September Brussels Meeting of the EU decentralised agencies
Cooperation with European and international partners
19 January Vienna UNDCP-EMCDDA working meeting
28–30 April Strasbourg 43rd Meeting of the permanent correspon-
dents of the Pompidou Group
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28 September Oporto FATF ad hoc working group: Estimating the
magnitude of drugs proceeds
28–29 September Strasbourg Signature of the memorandum of under-
standing between the EMCDDA and the
Council of Europe (Pompidou Group)
Meeting between Secretary-General of the
Council of Europe, Walter Schwimmer, and
EMCDDA Executive Director, Georges
Estievenart 
15 October The Hague Annual meeting of the EMCDDA and Europol 
4–5 November Strasbourg 44th Meeting of permanent correspondents of
the Pompidou Group
5 November The Hague FATF ad hoc working group: Estimating the
magnitude of drugs proceeds
6–10 December Vienna UNDCP expert working group on improving
intersectoral impact in drug-abuse offenders
casework (see Chapter 4)
Developing cooperation with third countries
7–8 April Panama Second high-level preparatory experts meet-
ing: Coordination and cooperation mechanism
between the European Union, Latin America
and the Caribbean — Comprehensive action
plan on drugs
3–7 May Washington 25th regular meeting of the Inter-American
Drug Abuse Control Commission (CICAD)
17–21 May Madrid First general assembly of the Ibero-American
network of NGOs
4–7 October Montevideo 26th regular meeting of the Inter-American
Drug Abuse Control Commission (CICAD)
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Practical information
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
Rua da Cruz de Santa Apólonia 23–25
P-1149-045 Lisbon
Tel. (351) 218 11 30 00
Fax (351) 218 13 17 11
E-mail: info@emcdda.org
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